<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003775.pub2" GROUP_ID="LIVER" ID="169101101521145511" MERGED_FROM="" MODIFIED="2008-11-09 13:55:09 +0100" MODIFIED_BY="Dimitrinka Nikolova" NOTES="&lt;p&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 13:50:42 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="01" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2008-11-09 13:55:09 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE>Hepatitis B vaccination for patients with chronic renal failure</TITLE>
<CONTACT>
<PERSON ID="14069" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>James</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Zacharias</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Professor</POSITION>
<EMAIL_1>jzacharias@hsc.mb.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Section of Nephrology</DEPARTMENT>
<ORGANISATION>University of Manitoba</ORGANISATION>
<ADDRESS_1>Ge441B - 820 Sherbrook St</ADDRESS_1>
<ADDRESS_2>Health Sciences Centre</ADDRESS_2>
<CITY>Winnipeg</CITY>
<ZIP>R3A 1R9</ZIP>
<REGION>Manitoba</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 204 787 7001</PHONE_1>
<PHONE_2/>
<FAX_1>204 787 3326</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-11-09 12:38:38 +0100" MODIFIED_BY="[Empty name]">
<PERSON ID="95D61EB182E26AA201C330AAD0EDB520" MODIFIED="2008-11-09 12:38:02 +0100" MODIFIED_BY="[Empty name]" NOTES="Created from byline" NOTES_MODIFIED="2008-11-09 12:38:02 +0100" NOTES_MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Robert J</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Schroth</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Professor</POSITION>
<EMAIL_1>umschrot@cc.umanitoba.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Dental Diagnostic &amp; Surgical Sciences</DEPARTMENT>
<ORGANISATION>University of Manitoba D341-Faculty of Dentistry</ORGANISATION>
<ADDRESS_1>780 Bannatyne Avenue</ADDRESS_1>
<ADDRESS_2/>
<CITY>Winnipeg Manitoba</CITY>
<ZIP>R3E OW2</ZIP>
<REGION/>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="95FA796482E26AA20024ED7855D5BFE2" MODIFIED="2008-11-09 12:38:15 +0100" MODIFIED_BY="[Empty name]" NOTES="Created from byline" NOTES_MODIFIED="2008-11-09 12:38:15 +0100" NOTES_MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Carol A</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hitchon</LAST_NAME>
<SUFFIX>MD FRCPC</SUFFIX>
<POSITION>Assistant Professor</POSITION>
<EMAIL_1>umhitcho@cc.umanitoba.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Internal Medicine</DEPARTMENT>
<ORGANISATION>University of Manitoba RR149 Rehabilitation Hospital</ORGANISATION>
<ADDRESS_1>800 Sherbrook St</ADDRESS_1>
<ADDRESS_2/>
<CITY>Winnipeg Manitoba</CITY>
<ZIP>R3A 1M4</ZIP>
<REGION/>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 204 787 1851</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14060" MODIFIED="2008-11-09 12:38:19 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Julia</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Uhanova</LAST_NAME>
<SUFFIX>MD MSc</SUFFIX>
<POSITION>Lecturer</POSITION>
<EMAIL_1>uhanovaj@cc.umanitoba.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Internal Medicine</DEPARTMENT>
<ORGANISATION>University of Manitoba 803B John Buhler Research Centre</ORGANISATION>
<ADDRESS_1>727 Mc Dermont Avenue</ADDRESS_1>
<ADDRESS_2/>
<CITY>Winnipeg Manitoba</CITY>
<ZIP>R3E 3P5</ZIP>
<REGION>Manitoba</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 204 789 3502</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14030" MODIFIED="2008-11-09 12:38:24 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Ayman</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Noreddin</LAST_NAME>
<SUFFIX/>
<POSITION>Research Associate</POSITION>
<EMAIL_1>anoreddin@hsc.mb.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Medical Microbiology</DEPARTMENT>
<ORGANISATION>Faculty of Medicine, University of Manitoba</ORGANISATION>
<ADDRESS_1>MS673 - 820 Sherbrook St</ADDRESS_1>
<ADDRESS_2>Health Sciences Centre</ADDRESS_2>
<CITY>Winnipeg</CITY>
<ZIP>R3A 1R9</ZIP>
<REGION>Manitoba</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 204 787 4683</PHONE_1>
<PHONE_2/>
<FAX_1>1-204-787-4699</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="95D6407182E26AA201C330AAA0081606" MODIFIED="2008-11-09 12:38:29 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Shayne</FIRST_NAME>
<MIDDLE_INITIALS>P</MIDDLE_INITIALS>
<LAST_NAME>Taback</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Professor</POSITION>
<EMAIL_1>tabacksp@cc.umanitoba.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Pediatrics and Child Health</DEPARTMENT>
<ORGANISATION>University of Manitoba</ORGANISATION>
<ADDRESS_1>FE325-685 William Ave</ADDRESS_1>
<ADDRESS_2>820 Sherbrook Street</ADDRESS_2>
<CITY>Winnipeg</CITY>
<ZIP>R3E 0Z2</ZIP>
<REGION>Manitoba</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>204 787 7435</PHONE_1>
<PHONE_2/>
<FAX_1>204 787 1655</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="95D33E4D82E26AA201C330AA27420B63" MODIFIED="2008-11-09 12:38:33 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Michael</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Moffatt</LAST_NAME>
<SUFFIX>MD, Msc, FRCPC</SUFFIX>
<POSITION>Executive Director</POSITION>
<EMAIL_1>mmoffatt@wrha.mb.ca</EMAIL_1>
<EMAIL_2>MMoffatt@exchange.hsc.mb.ca</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Research &amp; Applied Learning</DEPARTMENT>
<ORGANISATION>Winnipeg Regional Health Authority</ORGANISATION>
<ADDRESS_1>1800-155 Carlton Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Winnipeg</CITY>
<ZIP>R3C 4Y1</ZIP>
<REGION>Manitoba</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 204 926 7835</PHONE_1>
<PHONE_2/>
<FAX_1>+1 204 926 7007</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14069" MODIFIED="2008-11-09 12:38:38 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>James</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Zacharias</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Professor</POSITION>
<EMAIL_1>jzacharias@hsc.mb.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Section of Nephrology</DEPARTMENT>
<ORGANISATION>University of Manitoba</ORGANISATION>
<ADDRESS_1>Ge441B - 820 Sherbrook St</ADDRESS_1>
<ADDRESS_2>Health Sciences Centre</ADDRESS_2>
<CITY>Winnipeg</CITY>
<ZIP>R3A 1R9</ZIP>
<REGION>Manitoba</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 204 787 7001</PHONE_1>
<PHONE_2/>
<FAX_1>204 787 3326</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-11-09 13:55:09 +0100" MODIFIED_BY="Dimitrinka Nikolova" NOTES="&lt;p&gt;Minor update: 24/05/04&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 29/11/03&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 12:38:50 +0100" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="24" MONTH="5" YEAR="2004"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="29" MONTH="11" YEAR="2003"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="27" MONTH="5" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2004"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="9" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-11-09 12:39:09 +0100" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Canadian Cochrane Centre Network - University of Manitoba Site Group - Dr. Michael EK Moffatt</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-09 13:50:42 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>Hepatitis B vaccines achieve antibody production in patients with chronic renal failure, but we do not know if the vaccines are protective</TITLE>
<SUMMARY_BODY>
<P>Patients with chronic renal failure are at increased risk of hepatitis B virus infections. This review was undertaken to determine the beneficial and harmful effects of vaccination against hepatitis B and of a reinforced recombinant vaccination series. None of the trials had high methodological quality. Plasma vaccine was significantly more effective than placebo in achieving hepatitis B antibodies. Yet no statistically significant difference was found between the use of plasma vaccine or placebo in preventing hepatitis B virus infections. No trials comparing recombinant vaccine with placebo were identified. There was no significant difference between recombinant and plasma vaccines or between a reinforced vaccination series and routine vaccinations of three inoculations using recombinant vaccine regarding achieving hepatitis B antibodies.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Chronic renal failure patients are at particular risk of hepatitis B virus infection. Early studies have demonstrated that renal failure patients benefit from vaccination; however, not all studies have consistently shown benefit. <BR/>
</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the beneficial and harmful effects of hepatitis B vaccine and of a reinforced vaccination series in chronic renal failure patients.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched <I>The Cochrane Hepato-Biliary Group Controlled Trials Register</I>, <I>The Cochrane Renal Group Controlled Trials Register</I>, <I>The Cochrane Controlled Trials Register </I>on <I>The Cochrane Library (Issue 1, 2002),</I>
<I>PubMed/MEDLINE</I> (1966 to July 2003), <I>EMBASE</I> (1985 to November 2003), <I>Current Clinical Practice Guidelines</I> (Canadian Immunization Guide and Vaccine Preventable Diseases Surveillance Manual), and <I>Science Citation Index</I> as well as journals, published abstracts, and reference lists of articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised clinical trials comparing plasma vaccine with placebo, recombinant vaccine with placebo, recombinant vaccine with plasma vaccine, and a reinforced vaccination series (ie, more than three inoculations) with three inoculations of vaccine in chronic renal failure patients.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Primary outcome measures included incidence of patients developing hepatitis B virus antibodies and infections while secondary outcomes included adverse events, liver-related morbidity, and mortality. Random effects models were used and reported relative risks and 95% confidence intervals (RR and 95% CI). </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>We included seven randomised clinical trials. None of them had high quality. Plasma vaccine was significantly more effective than placebo in achieving hepatitis B antibodies (RR 23.0, 95% CI 14.39 to 36.76, 3 trials). We found no statistically significant difference between plasma vaccine or placebo regarding hepatitis B virus infections (RR 0.50, 95% CI 0.20 to 1.24). We found no statistically significant differences between recombinant vaccine and plasma vaccine in achieving hepatitis B antibodies (RR 0.65, 95% CI 0.28 to 1.53, 2 trials). Heterogeneity was significant and appeared to be attributable to the dose of vaccine. Two trials examined a reinforced recombinant vaccine strategy, which was not statistically more effective than three inoculations of recombinant vaccine regarding development of hepatitis B antibodies (RR 1.36, 95% CI 0.85 to 2.16).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Plasma derived vaccines are more effective than placebo in achieving hepatitis B antibodies, while no statistically significant difference was found between recombinant and plasma vaccines. No statistically significant difference of effectiveness was observed between a reinforced vaccination series versus routine vaccinations of three inoculations of recombinant vaccine. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-09 13:50:42 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-11-09 12:39:34 +0100" MODIFIED_BY="[Empty name]">
<P>Hepatitis B virus (HBV) is one of the most frequent viral infections in humans with estimates of 200 to 500 million infected people worldwide (<LINK REF="REF-Specter-1999" TYPE="REFERENCE">Specter 1999</LINK>; <LINK REF="REF-Fabrizi-2000" TYPE="REFERENCE">Fabrizi 2000</LINK>). Infection can occur either through perinatal transmission, which is the cause of 35 to 40 per cent of new infections worldwide (<LINK REF="REF-Fabrizi-2000" TYPE="REFERENCE">Fabrizi 2000</LINK>) or horizontally through exposure to infected blood or other body fluids. While the perinatal (vertical) mode of transmission is of increasing concern in specific geographic regions (<LINK REF="REF-Fabrizi-2000" TYPE="REFERENCE">Fabrizi 2000</LINK>) much more attention has been focused on the horizontal transmission of the HBV among high-risk populations. The high-risk population for horizontal transmission includes health-care workers, chronic renal failure (CRF) patients (<LINK REF="REF-Torres-1996" TYPE="REFERENCE">Torres 1996</LINK>; <LINK REF="REF-Jefferson-2000" TYPE="REFERENCE">Jefferson 2000</LINK>), and homosexual men (<LINK REF="REF-MacKellar-2001" TYPE="REFERENCE">MacKellar 2001</LINK>).</P>
<P>CRF patients are at particular risk of HBV infection due to their increased exposure to blood products, haemodialysis (<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>; <LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>; <LINK REF="STD-Jilg-1986a" TYPE="STUDY">Jilg 1986a</LINK>; <LINK REF="STD-Seaworth-1988a" TYPE="STUDY">Seaworth 1988a</LINK>; <LINK REF="REF-Dukes-1993" TYPE="REFERENCE">Dukes 1993</LINK>; <LINK REF="STD-El_x002d_Reshaid-1994" TYPE="STUDY">El-Reshaid 1994</LINK>; <LINK REF="STD-Jungers-1994a" TYPE="STUDY">Jungers 1994a</LINK>), and an impaired immune response (<LINK REF="REF-Revillard-1979" TYPE="REFERENCE">Revillard 1979</LINK>; <LINK REF="REF-Chatenoud-1986" TYPE="REFERENCE">Chatenoud 1986</LINK>; <LINK REF="REF-Chatenoud-1990" TYPE="REFERENCE">Chatenoud 1990</LINK>; <LINK REF="REF-Johnson-1992" TYPE="REFERENCE">Johnson 1992</LINK>). The impaired immune response affects hepatitis B vaccine efficacy. Cases of infections among renal patients undergoing dialysis are generally mild, but up to 80 per cent may progress into chronic carriers. This poses risk to other haemodialysis recipients in the same clinical facility (<LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>; <LINK REF="STD-Stevens-1984" TYPE="STUDY">Stevens 1984</LINK>; <LINK REF="REF-Huang-1997" TYPE="REFERENCE">Huang 1997</LINK>). Liver-related morbidity including cirrhosis and hepatocellular carcinoma may also develop. Occurrences of chronic hepatitis in the haemodialysed populace have ranged from 3 to 29 per cent (<LINK REF="REF-Huang-1997" TYPE="REFERENCE">Huang 1997</LINK>) and the estimated prevalence of HBV infection has previously been reported to be 1.1 to 6.1 per cent in dialysis patients worldwide (<LINK REF="REF-Geerlings-1991" TYPE="REFERENCE">Geerlings 1991</LINK>; <LINK REF="REF-Petrosillo-1993" TYPE="REFERENCE">Petrosillo 1993</LINK>; <LINK REF="REF-Tokars-1998" TYPE="REFERENCE">Tokars 1998</LINK>). Current data from the United States indicate that the prevalence of HBV infections among those receiving maintenance haemodialysis is 0.9 per cent (<LINK REF="REF-Tokars-2000" TYPE="REFERENCE">Tokars 2000</LINK>) while the prevalence of HBV infections among dialysis patients in the developing world range from 12 to 21.6 per cent (<LINK REF="REF-Fabrizi-2001" TYPE="REFERENCE">Fabrizi 2001</LINK>).</P>
<P>Transmission of hepatitis B may be prevented through the administration of hepatitis B vaccine to persons at risk. The first hepatitis vaccine was derived from pooled hepatitis B surface antigen positive plasma and was licensed in the United States of America in 1981 (<LINK REF="REF-Fabrizi-2000" TYPE="REFERENCE">Fabrizi 2000</LINK>). Today, recombinant vaccines have largely replaced it (<LINK REF="STD-Jilg-1986a" TYPE="STUDY">Jilg 1986a</LINK>; <LINK REF="STD-El_x002d_Reshaid-1994" TYPE="STUDY">El-Reshaid 1994</LINK>; <LINK REF="REF-Zannolli-1997" TYPE="REFERENCE">Zannolli 1997</LINK>).</P>
<P>Vaccination efficacy of hepatitis B vaccine may be determined by measuring the serum titres of antibody to the hepatitis B surface antigen (HBsAg). Seroconversion can be used as surrogate marker for protection against hepatitis B (<LINK REF="REF-Popper-1990" TYPE="REFERENCE">Popper 1990</LINK>). Titres greater than 10 milli international units per millilitre (mIU/mL, ie, 10 IU/L) or greater than 10 Sample Ratio Units (SRU) are generally considered protective (<LINK REF="REF-Popper-1990" TYPE="REFERENCE">Popper 1990</LINK>). While seroconversion is generally a useful surrogate marker, for some populations it may be inadequate thus necessitating the study of both seroconversion and HBV infections. A systematic review of effectiveness of these vaccines in health-care workers (<LINK REF="REF-Jefferson-2000" TYPE="REFERENCE">Jefferson 2000</LINK>) has shown benefits. Early studies have demonstrated that renal-failure patients benefit from vaccination. However, many have incomplete seroconversion with rates ranging from 32 to 80 per cent, and not all studies have consistently shown benefit (<LINK REF="REF-Fabrizi-2000" TYPE="REFERENCE">Fabrizi 2000</LINK>). The Advisory Committee on Immunization Practices recommends a four-dose schedule of recombinant Engerix B (40 µg) vaccine in renal patients over 20 years of age (<LINK REF="REF-Rangel-2000" TYPE="REFERENCE">Rangel 2000</LINK>). The current Center for Disease Control (CDC) recommendations for vaccination of renal patients over 20 years of age also specifies a four dose recombinant vaccine schedule of 40 µg Engerix B at 0, 1, 2, and 6 months (<LINK REF="REF-CDC-2001" TYPE="REFERENCE">CDC 2001</LINK>). Various strategies employed in HBV vaccination in this population include increased doses of vaccine, reinforced vaccination strategies, and different schedules of vaccine administration (<LINK REF="STD-Jilg-1986a" TYPE="STUDY">Jilg 1986a</LINK>; <LINK REF="STD-Seaworth-1988a" TYPE="STUDY">Seaworth 1988a</LINK>; <LINK REF="STD-El_x002d_Reshaid-1994" TYPE="STUDY">El-Reshaid 1994</LINK>). Trials which have investigated variations in vaccine dose, dose scheduling, and the use of adjuvants to enhance seroconversion rates have had variable results (<LINK REF="REF-Fabrizi-2000" TYPE="REFERENCE">Fabrizi 2000</LINK>). Thus the optimum strategy for immunizing CRF patients is not clear.</P>
<P>We have been unable to identify systematic reviews or meta-analyses on hepatitis B vaccination for CRF patients. This systematic review investigates the effectiveness and safety of hepatitis B vaccination in providing adequate seroconversion in CRF patients and preventing hepatitis B infections.</P>
</BACKGROUND>
<OBJECTIVES>
<UL>
<LI>To identify the beneficial and harmful effects of hepatitis B vaccine in CRF patients.</LI>
<LI>To identify the beneficial and harmful effects of a reinforced vaccination series (three inoculations plus one or more booster inoculations) against a vaccination series of three inoculations using hepatitis B vaccine.</LI>
</UL>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-09 13:50:42 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-11-09 13:50:42 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2008-11-09 12:44:45 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
<BR/>
</P>
<UL>
<LI>Randomised clinical trials studying the administration of hepatitis B vaccine to CRF patients, with or without dialysis.</LI>
<LI>No language, publication date, or publication status restrictions were imposed.</LI>
</UL>
<P>
<B>Exclusion criteria</B>
<BR/>
</P>
<UL>
<LI>Quasi-randomised trials.</LI>
</UL>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>
<B>Inclusion criteria</B>
<BR/>
</P>
<UL>
<LI>Participants of any age with CRF or receiving dialysis (haemodialysis or peritoneal dialysis) were considered. CRF was defined as serum creatinine greater than 200 µmol/L for a period of more than six months or individuals receiving dialysis (haemodialysis or peritoneal dialysis).</LI>
<LI>Participants who were seronegative for HBsAg and seronegative for anti-HBsAg antibodies or unsuccessfully vaccinated against HBV (&lt; 10 SRU, &lt; 10 mIU/mL, &lt; 10 IU/L, or equivalent) (<LINK REF="REF-Popper-1990" TYPE="REFERENCE">Popper 1990</LINK>; <LINK REF="REF-Alexander-1998" TYPE="REFERENCE">Alexander 1998</LINK>) prior to vaccine administration were included (See Additional Tables 01 and 02).</LI>
</UL>
<P>
<B>Exclusion criteria</B>
<BR/>
</P>
<UL>
<LI>Renal transplant patients were excluded from this review as these individuals are immunosuppressed and are receiving immunosuppressant agents to prevent rejection of their transplanted organs (<LINK REF="REF-Johnson-1992" TYPE="REFERENCE">Johnson 1992</LINK>; <LINK REF="REF-Lefebure-1993" TYPE="REFERENCE">Lefebure 1993</LINK>; <LINK REF="REF-Huang-1997" TYPE="REFERENCE">Huang 1997</LINK>; <LINK REF="REF-Fivush-1998" TYPE="REFERENCE">Fivush 1998</LINK>), and they have essentially normal renal function (<LINK REF="REF-Feuerhake-1984" TYPE="REFERENCE">Feuerhake 1984</LINK>). </LI>
<LI>Participants infected with the HBV or with evidence of potential infection (elevated transaminases) were excluded.</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>
<B>Inclusion criteria<BR/>
</B>
</P>
<UL>
<LI>Trials comparing the beneficial and harmful effects of hepatitis B vaccines with adjuvant or cytokine co-interventions. </LI>
<LI>Trials comparing the beneficial and harmful effects of immunoglobulin prophylaxis. This review was limited to studies looking at active immunization.</LI>
<LI>Hepatitis B vaccines (plasma or recombinant (yeast) derived) of all types, dose, and regimens versus placebo, control vaccine, or no vaccine.</LI>
<LI>Reinforced schedules of vaccine of three inoculations plus one or more booster inoculations versus standard vaccination with three inoculations of vaccine. </LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-09 13:50:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome measures</B>
<BR/>
</P>
<UL>
<LI>Seroconversion, ie, proportion of patients with adequate anti-HBs response (&gt; 10 IU/L or SRU) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</LI>
<LI>Hepatitis B infections (as measured by hepatitis B core antigen (HBcAg) positivity or persistent HBsAg positivity), both acute and chronic. Acute (primary) HBV infections were defined as seroconversion to HBsAg positivity or development of IgM anti-HBc. Chronic HBV infections were defined as the persistence of HBsAg for more than six months or HBsAg positivity and liver biopsy compatible with a diagnosis or chronic hepatitis B.</LI>
</UL>
<P>
<B>Secondary outcome measures</B>
<BR/>
</P>
<UL>
<LI>Adverse events of hepatitis B vaccinations were recorded and were categorized as:</LI>
</UL>
<P>i) Local injection-site adverse events (as defined in included studies).<BR/>ii) Systemic adverse events.<BR/>
</P>
<UL>
<LI>Liver-related morbidity (elevated transaminases, cirrhosis, hepatocellular carcinoma).</LI>
<LI>Mortality.</LI>
</UL>
<P>Where outcomes were reported at various intervals during the randomised trials, we analysed the outcomes reported at the longest period following vaccinations.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-09 12:45:20 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>We searched <I>The Cochrane Hepato-Biliary Group Controlled Trials Register</I>, <I>The Cochrane Renal Group Controlled Trials Register</I>, and <I>The Cochrane Controlled Trials Register</I> (<I>Cochrane Library </I>Issue 1, 2002) were searched.</LI>
<LI>We conducted electronic searches utilizing <I>PubMed/MEDLINE</I> (1966 to July 2003) and <I>EMBASE</I> (Excerpta Medica Database) (1985 to 2003) databases (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the search strategies and MESH terms utilized). Both MESH and non-MESH terms were used.</LI>
<LI>We searched <I>Science Citation Index</I> (Web of Science) utilizing search terms similar to those used for the <I>PubMed/MEDLINE</I> and <I>EMBASE</I> searches.</LI>
<LI>We searched published abstracts and proceedings from key scientific conferences of renal, hepatology, and immunology societies to identify any trials not published in journal format. This included the <I>Journal American Society of Nephrology, Nephrology Dialysis Transplant</I> - <I>European Dialysis Transplant Association</I>, <I>Hepatology, Journal of Hepatology,American Association for the Study of Liver Diseases</I>, and <I>Vaccine</I> from 1980 to 2002.</LI>
<LI>We searched current clinical practice guidelines (<I>Canadian Immunization Guide </I>and<I> Vaccine Preventable Diseases Surveillance Manual</I>) for relevant randomised clinical trials.</LI>
<LI>We hand searched reference lists from review articles retrieved from <I>PubMed/MEDLINE</I> and reference lists from randomised clinical trials to identify additional trials.</LI>
</UL>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-09 12:43:49 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Application of inclusion criteria</B>
<BR/>We conducted this systematic review and reported findings according to the 'Quality of reporting of meta-analysis guidelines' (QUORUM) (<LINK REF="REF-Moher-1999" TYPE="REFERENCE">Moher 1999</LINK>; <LINK REF="REF-Walker-1999" TYPE="REFERENCE">Walker 1999</LINK>) and according to the recommendations of The Cochrane Collaboration in The Cochrane Reviewers' Handbook (<LINK REF="REF-Clarke-2001" TYPE="REFERENCE">Clarke 2001</LINK>).<BR/>
</P>
<UL>
<LI>We assessed titles of research articles retrieved from the electronic database and hand searches to determine which abstracts should be reviewed for possible inclusion as per the reviewers defined eligibility criteria described under 'Types of studies', 'Types of participants', 'Types of interventions', and 'Types of outcome measures'.</LI>
<LI>All abstracts were assessed using the eligibility criteria proposed by the reviewers for selecting papers.</LI>
<LI>We listed excluded trials with the reasons for exclusion.</LI>
<LI>We resolved discrepancies between individual reviewers through consensus.</LI>
</UL>
<P>
<B>Data extraction</B>
<BR/>We performed data extraction on all randomised clinical trials meeting eligibility criteria and review objectives. To ensure accuracy, a minimum of three reviewers independently extracted data from each trial.</P>
<P>Data extraction included:<BR/>(1) Number of participants in each randomised controlled trial and the number enrolled to receive each intervention.<BR/>(2) Demographic composition and baseline clinical information for each intervention group. This included, when specified, age, gender, stage of renal disease, dialysis status (haemodialysis, peritoneal dialysis, and average number of years on dialysis), previous vaccination status (previous vaccination attempts, previously unvaccinated, or unknown), previous antigen status before receiving trial intervention (HBsAg negative, anti-HBsAg negative), and participant withdrawals or dropouts.<BR/>(3) Types of interventions employed (plasma vaccine versus placebo, recombinant vaccine versus plasma vaccine, reinforced vaccination series (three inoculations plus one or more booster inoculations)) versus standard vaccination series (three inoculations).<BR/>(4) Information relating to the vaccines (or placebo), the trade name, dose, number of doses utilized in the trial, the immunization schedules utilized (in months, with first inoculation = 0 months), and route of vaccination if indicated.<BR/>(5) Information concerning the primary outcomes utilized in each included randomised clinical trial, the type of immunoassay employed, and the time of assessment of outcomes.<BR/>(6) Primary outcomes collected included the definition of seroconversion in each trial (SRU or IU/L) and the number seroconverted in each group, the definition of partial seroconversion, and the number partially seroconverted if given, and the number of active hepatitis B infections in each group (both acute and chronic).<BR/>(7) Secondary outcomes collected included the number of adverse events, deaths, and liver-related morbidity.</P>
<P>
<B>Methodological quality</B>
<BR/>The methodological quality, defined as the confidence that the design and report will restrict bias in the intervention comparison (<LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>), was evaluated independently and unblinded by a minimum of two reviewers. According to empirical evidence (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>), we assessed the methodological quality of all randomised clinical trials meeting the criteria and objectives of this review by using separate components, ie, generation of the allocation sequence, allocation concealment, blinding, follow-up, and use of intention-to-treat analyses. Components were assessed as adequate, unclear, or inadequate:</P>
<P>(1) Generation of the allocation sequence: adequate (computer generated random numbers or similar), or unclear (not described), or inadequate (other methods).<BR/>(2) Allocation concealment: adequate (central independent unit, sealed envelopes, or similar), or unclear (not described), or inadequate (open table of random numbers or similar). In the Table of Characteristics of Included Studies A = adequate, B = unclear, C = inadequate.<BR/>(3) Blinding: adequate (double blind (blinding of both participants and investigators) and identical placebo tablets or similar), or unclear (not described), or not performed (tablets versus injections, or similar).<BR/>(4) Follow-up: adequate (number and reasons for dropouts and withdrawals described), or unclear (if the report gave impression that there had been no dropouts or withdrawals, but this was not specifically stated), or inadequate (number or reasons for dropouts and withdrawals were not described).</P>
<P>
<B>Statistical analysis<BR/>
</B>We entered data extracted from included randomised controlled trials into Review Manager 4.2.6. software for statistical analysis. The random effects model was used. Data synthesis was carried out as follows:</P>
<P>- Relative risk and 95% confidence intervals were computed.<BR/>- Chi-squared testing for heterogeneity was performed. A P value of 0.1 was selected (<LINK REF="REF-Engels-2000" TYPE="REFERENCE">Engels 2000</LINK>).<BR/>- Homogeneity of interventions, participants, and outcomes was assessed prior to combining extracted data from different included randomised clinical trials being compared.<BR/>- Variability among trial results was expected, and possibilities included dose, route, frequency, and timing of vaccine administration, along with the populations reported, and the length of follow-up.<BR/>- Significant heterogeneity encountered required explanation by the reviewers.<BR/>- The reviewers exercised caution when facing the dilemma of low methodological quality for a significant number of included trials.<BR/>- The results were analysed with intention-to-treat analyses to study beneficial effects.<BR/>- Where comparisons involved a small number of included trials, caution was exercised when interpreting meta-analyses..<BR/>- 'Subgroup analysis' was performed in cases where comparisons between interventions being considered demonstrated significant heterogeneity.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-09 12:46:50 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-11-09 12:45:54 +0100" MODIFIED_BY="[Empty name]">
<P>Following the <I>PubMed</I> electronic database search using the search strategy (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), we conducted a title search on 954 listed citations, of which 171 abstracts were reviewed. We retrieved one hundred eight full text journal articles including both trials (n = 75) and review articles (n = 33). Only 12 articles were randomised clinical trials that met the criteria for this review. These articles described a total of seven randomised trials.</P>
<P>We conducted a subsequent modified search strategy to detect randomised clinical trials in <I>PubMed, </I>which resulted in 23 unique trials. We then reviewed titles and abstracts of these and obtained five full text articles. However, none met the inclusion criteria.</P>
<P>We searched reference lists of identified journal articles but did not identify any additional trials meeting our inclusion criteria.</P>
<P>An electronic search of <I>EMBASE</I> retrieved 772 titles, of which 102 abstracts were reviewed. Eighty-six full articles were reviewed; however, none met our inclusion criteria.</P>
<P>The Web of Science electronic search (<I>Science Citation Index</I>) produced 10 titles of which four abstracts were reviewed. No unique randomised trials were found.</P>
<P>Thus we excluded a total of seven randomised clinical trials from this review while another seven met the specified objectives and inclusion criteria. Three trials investigated plasma vaccines versus placebo (<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>; <LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>; <LINK REF="STD-Stevens-1984" TYPE="STUDY">Stevens 1984</LINK>). Two trials investigated the comparison of recombinant and plasma vaccines (<LINK REF="STD-Jungers-1994a" TYPE="STUDY">Jungers 1994a</LINK>; <LINK REF="STD-Seaworth-1988a" TYPE="STUDY">Seaworth 1988a</LINK>). Another two trials compared a reinforced schedule of recombinant vaccine with a vaccination series of three inoculations of recombinant vaccine (<LINK REF="STD-El_x002d_Reshaid-1994" TYPE="STUDY">El-Reshaid 1994</LINK>; <LINK REF="STD-Jilg-1986a" TYPE="STUDY">Jilg 1986a</LINK>) (See Table of Characteristics of Included Studies).</P>
<P>
<B>Plasma derived hepatitis B vaccine versus placebo </B>
<BR/>
<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>
<BR/>This randomised, double-blinded, placebo-controlled trial reported the use of plasma vaccine (Institut Pasteur Production Vaccine) 5 µg versus placebo, both administered at 0, 1, and 2 months. Participants were haemodialysis patients. Outcomes included seroconversion, HBV infections, and adverse events at 12 months.</P>
<P>
<LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>
<BR/>This randomised, double-blinded, and placebo-controlled investigated heat-inactivated (CLB) plasma vaccine 3 µg versus placebo for haemodialysis recipients. Inoculations were performed at 0, 1, 2, and 4 months. Outcomes included seroconversion, partial seroconversion, HBV infections, and adverse events at approximately 14 months.</P>
<P>
<LINK REF="STD-Stevens-1984" TYPE="STUDY">Stevens 1984</LINK>
<BR/>This randomised trial of haemodialysis patients involved the comparison of Heptavax B vaccine 40 µg at 0, 1, and 6 months against placebo. Outcomes reported included seroconversions and HBV infections at 24 months.</P>
<P>
<B>Recombinant vaccine versus plasma vaccine</B>
<BR/>Jungers 1994<BR/>This randomised trial involved chronic uremic patients. GenHevac B (recombinant) vaccine 20 µg with inoculations occurring at 0, 1, 2, 4, and 12 months was compared with Hevac B (plasma) vaccine 5 µg at 0,1,2,4, and 12 months. Outcomes included both seroconversions and partial seroconversions at 12 months.</P>
<P>
<LINK REF="STD-Seaworth-1988a" TYPE="STUDY">Seaworth 1988a</LINK>
<BR/>This randomised trial involved CRF patients. This trial compared recombinant and plasma vaccines. Recombivax vaccine 20 µg administered at 0,1,and 6 months was compared with Heptavax B (plasma) vaccine 40 µg at 0, 1, 6 months. Another comparison involved Recombivax 40 µg at 0, 1, 6 months against Heptavax B 40 µg at 0, 1, and 6 months. We divided the data of the plasma vaccine arm in half in order to undertake the statistical comparisons. Both seroconversions and partial seroconversions at 12 months were reported.</P>
<P>
<B>Reinforced vaccination series versus three inoculation vaccination series</B>
<BR/>
<LINK REF="STD-El_x002d_Reshaid-1994" TYPE="STUDY">El-Reshaid 1994</LINK>
<BR/>This was a randomised, single-blinded trial assessing a reinforced vaccination series (three inoculations plus one or more booster inoculations) against a vaccination series of three inoculations using recombinant hepatitis B vaccine. Participants were on either peritoneal dialysis or haemodialysis. Engerix B 40 µg was administered at 0, 1, and 6 months for one arm, while another arm received Engerix B 40 µg at 0, 1, 2, and 6 months. This study also involved an arm of participants receiving Engerix B 20 µg at 0, 1, 2, and 6 months but this arm was excluded for the purposes of this review. Outcomes assessed included seroconversion at 24 months.</P>
<P>
<LINK REF="STD-Jilg-1986a" TYPE="STUDY">Jilg 1986a</LINK>
<BR/>This study was randomised and involved dialysis patients. Three intervention groups were employed, assessing a primary vaccination series of three inoculations against two reinforced vaccination campaigns utilizing a booster inoculation. Merck Sharp Dohme recombinant vaccine 40 µg at 0, 1, and 6 months was compared to the same vaccine dose using the schedule 0, 1, 2, 3, 4, and 5 months and to Merck Sharp Dohme recombinant vaccine 20 µg at 0, 1, 2, 3, 4, and 5 months. We divided the data of the three inoculations arm in half in order to undertake the statistical comparisons. Outcomes reported included seroconversions at 10 months.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-11-09 12:46:50 +0100" MODIFIED_BY="[Empty name]">
<P>The methodological quality of the included trials is described in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>. Of the seven trials, none reported on the generation of the allocation sequence, although the <LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK> trial described a code used for the generation of the allocation sequence. However, this information was found to be insufficient to determine the appropriateness of the generation of the allocation sequence. The allocation concealment was unclear in six trials, but one (<LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>) was found to have adequate allocation concealment. Three trials were double blinded and used placebo (<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>; <LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>; <LINK REF="STD-Stevens-1984" TYPE="STUDY">Stevens 1984</LINK>), and the remaining four were conducted without blinding. In five trials the number and reason for dropouts and withdrawals were either described (<LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>; <LINK REF="STD-Seaworth-1988a" TYPE="STUDY">Seaworth 1988a</LINK>; <LINK REF="STD-Stevens-1984" TYPE="STUDY">Stevens 1984</LINK>) or mentioned (<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>; <LINK REF="STD-Jungers-1994a" TYPE="STUDY">Jungers 1994a</LINK>). The <LINK REF="STD-El_x002d_Reshaid-1994" TYPE="STUDY">El-Reshaid 1994</LINK> trial had given the number of dropouts and withdrawals but did not provide explanations for these occurrences, while the <LINK REF="STD-Jilg-1986a" TYPE="STUDY">Jilg 1986a</LINK> trial completely failed to discuss participant withdrawals or dropouts.</P>
<P>The assessed methodological quality of the <LINK REF="STD-Jilg-1986a" TYPE="STUDY">Jilg 1986a</LINK> and <LINK REF="STD-El_x002d_Reshaid-1994" TYPE="STUDY">El-Reshaid 1994</LINK> studies was very low and the assessed methodological quality of <LINK REF="STD-Jungers-1994a" TYPE="STUDY">Jungers 1994a</LINK> and <LINK REF="STD-Seaworth-1988a" TYPE="STUDY">Seaworth 1988a</LINK> was equivalent, with both receiving modest scores. Accordingly, none of the trials was of high methodological quality, ie, having adequate generation of the allocation sequence, allocation concealment, blinding, and follow-up. However, as the important study outcomes were well-defined serologic responses and HBV infections, inadequate blinding may be of less concern.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>
<B>Plasma derived hepatitis B vaccine versus placebo</B>
<BR/>Rate of seroconversion<BR/>Three randomised clinical trials analysed the effectiveness of plasma derived vaccine versus placebo with 933 persons receiving plasma vaccine and 917 receiving placebo vaccination (<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>; <LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>; <LINK REF="STD-Stevens-1984" TYPE="STUDY">Stevens 1984</LINK>). Vaccination with plasma derived vaccine was found to be statistically more effective than placebo in achieving seroconversion and yielded a RR 23.00, 95% CI 14.39 to 36.76 (Comparison 01-01). The results were homogeneous (chi square = 0.36, df = 2, P = 0.83).</P>
<P>Only one trial provided sufficient information on partial seroconversions (<LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>) and indicated that partial seroconversions were greater among those in the plasma vaccine group (RR 21.52, 95% CI 10.89 to 42.53, P &lt; 0.00001 (Comparison 01-02)).</P>
<P>Hepatitis B infections<BR/>The use of plasma derived hepatitis B vaccine did not differ significantly from placebo in preventing active HBV infections and yielded a RR 0.50, CI 0.20 to 1.24 (Comparison 01-03) although a trend was seen in the direction of protection, with two studies showing benefit (<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>; <LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>). However, the analysis also revealed significant heterogeneity (chi squared value of 12.29, df = 2, P = 0.0021). Sensitivity analyses were performed on the data from the three trials to identify a possible source of the heterogeneity. One of the trials had a significantly larger population of persons, utilized larger dosages of vaccine, and assessed hepatitis outcomes at two years (<LINK REF="STD-Stevens-1984" TYPE="STUDY">Stevens 1984</LINK>) while the other two trials conducted assessments at 12 and 14 months (<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>; <LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>). The source of plasma vaccines also differed between the studies.</P>
<P>Adverse events and deaths<BR/>Two trials reported adverse events and deaths (<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>; <LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>). The use of plasma vaccine appeared to be well tolerated with no significant increase in deaths or adverse events. Both the group receiving plasma vaccine and the group receiving placebo reported a large number of adverse events presumed to be unrelated to the use of hepatitis B vaccine (<LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>) . </P>
<P>
<B>Recombinant versus plasma derived hepatitis B vaccine</B>
<BR/>Rate of seroconversion<BR/>Two randomised trials comparing recombinant versus plasma derived hepatitis B vaccines met the inclusion criteria (<LINK REF="STD-Seaworth-1988a" TYPE="STUDY">Seaworth 1988a</LINK>; <LINK REF="STD-Jungers-1994a" TYPE="STUDY">Jungers 1994a</LINK>). A total of 101 participants were inoculated with recombinant derived hepatitis B vaccine and 80 with plasma derived vaccine. One study (<LINK REF="STD-Seaworth-1988a" TYPE="STUDY">Seaworth 1988a</LINK>) involved two separate comparisons of recombinant vaccine, of differing dosages, to plasma vaccine. For the purposes of this review, we treated these two comparisons as separate studies and therefore we differentiated them by <LINK REF="STD-Seaworth-1988a" TYPE="STUDY">Seaworth 1988a</LINK> and <LINK REF="STD-Seaworth-1988b" TYPE="STUDY">Seaworth 1988b</LINK>. We halved the control group data. Although the use of recombinant vaccine was less effective in producing seroconversions than plasma derived vaccine, the difference was not significant (RR 0.65, 95% CI 0.28 to 1.53 (Comparison 02-01). Heterogeneity was significant (chi square = 10.22, df = 2, P = 0.006).</P>
<P>We conducted sensitivity analyses to determine possible origins of the heterogeneity. Combining the two recombinant groups in <LINK REF="STD-Seaworth-1988a" TYPE="STUDY">Seaworth 1988a</LINK> together to compare vaccine effectiveness, regardless of the dose of recombinant vaccine used, still tended to favour the use of plasma vaccine, although this was not significant (RR 0.75, 95% CI 0.29 to 1.92 (Comparison 02-03)). Heterogeneity also remained high (chi square = 9.02, df = 2, P = 0.0027). When only the high dose of recombinant vaccine arm in <LINK REF="STD-Seaworth-1988a" TYPE="STUDY">Seaworth 1988a</LINK> was used to compare plasma and recombinant vaccines, heterogeneity was eliminated (chi square = 2.61, df = 1, P = 0.11) and yielded a RR 0.96, 95% CI 0.58 to 1.57 (Comparison 02-04). </P>
<P>Comparison of partial and full seroconversions did not favour the use of recombinant derived vaccine over plasma vaccine and yielded a RR value of 0.97, 95% CI 0.69 to 1.38 (Comparison 02-02). This comparison also demonstrated homogeneity among the studies (chi square = 3.88, df = 2, P = 0.14).</P>
<P>Hepatitis B infections<BR/>There was insufficient information reported in the studies of <LINK REF="STD-Seaworth-1988a" TYPE="STUDY">Seaworth 1988a</LINK> and <LINK REF="STD-Jungers-1994a" TYPE="STUDY">Jungers 1994a</LINK> to assess whether recombinant vaccines differed from plasma derived vaccines in preventing hepatitis B infections.</P>
<P>Adverse events and deaths<BR/>There was insufficient information reported in the studies of <LINK REF="STD-Seaworth-1988a" TYPE="STUDY">Seaworth 1988a</LINK> and <LINK REF="STD-Jungers-1994a" TYPE="STUDY">Jungers 1994a</LINK> to assess deaths and adverse events from receiving recombinant or plasma vaccines. </P>
<P>
<B>Reinforced recombinant vaccination series versus three recombinant vaccine inoculations</B>
<BR/>Rate of seroconversion<BR/>Two randomised trials compared the effectiveness of a reinforced vaccination series with three inoculations of recombinant hepatitis B vaccine (<LINK REF="STD-Jilg-1986a" TYPE="STUDY">Jilg 1986a</LINK>; <LINK REF="STD-El_x002d_Reshaid-1994" TYPE="STUDY">El-Reshaid 1994</LINK>). In total 63 participants received a reinforced series of recombinant vaccine while 43 received three inoculations. One study (<LINK REF="STD-Jilg-1986a" TYPE="STUDY">Jilg 1986a</LINK>) involved two separate comparisons of three inoculations of 40 µg to six inoculations of 20 µg and six inoculations of 40 µg to three inoculations of 40 µg. These two separate comparisons within the same study were differentiated by the use of an asterisk (<LINK REF="STD-Jilg-1986a" TYPE="STUDY">Jilg 1986a</LINK>; <LINK REF="STD-Jilg-1986b" TYPE="STUDY">Jilg 1986b</LINK>). We halved the control group data. The initial analysis yielded a RR 1.36, 95% CI 0.85 to 2.16 (Comparison 03-01) and indicated that the reinforced series was not significantly more effective in achieving seroconversions than three inoculations. However, only 106 patients were studied and the possibility of a type II error cannot be excluded. Heterogeneity was insignificant (chi square = 2.59, df = 2, P = 0.27). </P>
<P>Hepatitis B infections<BR/>Insufficient data existed to assess whether a reinforced vaccination series was superior to a series of three inoculations of recombinant hepatitis B vaccine in preventing hepatitis B infections.</P>
<P>Adverse events and death<BR/>There was insufficient information reported in these two trials (<LINK REF="STD-Jilg-1986a" TYPE="STUDY">Jilg 1986a</LINK>; <LINK REF="STD-El_x002d_Reshaid-1994" TYPE="STUDY">El-Reshaid 1994</LINK>) to assess deaths and adverse events. <BR/>
</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>This is the first systematic review of the effectiveness of hepatitis B vaccinations in CRF patients. Seroconversion following hepatitis B vaccination can be used as surrogate marker for protection against hepatitis B (<LINK REF="REF-Popper-1990" TYPE="REFERENCE">Popper 1990</LINK>). The results of this review indicate that the use of plasma derived vaccine is effective in achieving seroconversion. However, reductions in HBV infections could not be demonstrated in this population given the wide confidence intervals, the heterogeneity, and the non-significant overall effect. Plasma vaccine is significantly more effective than placebo in achieving seroconversion. Recombinant vaccine may be as effective as plasma vaccine in achieving seroconversion. A significant benefit to the use of a reinforced recombinant vaccination series in patients with CRF over the use of three inoculations could not be proven. </P>
<P>Despite a thorough search of the literature we found only seven randomised trials matching the inclusion criteria selected for this review. Although the search for relevant literature was extensive, publication bias cannot be disregarded, as trials with negative results may have been less likely to be published. While the relatively small number of included trials is a limitation of this review, the comparisons between the use of plasma vaccine and placebo involved a large number of participants (n = 1850) (<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>; <LINK REF="STD-Stevens-1984" TYPE="STUDY">Stevens 1984</LINK>). The included trials may not have been designed with sufficient power to detect statistically significant differences between HBV infections in the plasma and placebo groups as infection rates were low in some of the studies (<LINK REF="STD-Stevens-1984" TYPE="STUDY">Stevens 1984</LINK>). As infections occurred in those who had previously seroconverted, seroconversion may not be universally protective in renal failure patients (<LINK REF="STD-Stevens-1984" TYPE="STUDY">Stevens 1984</LINK>). In addition, the mean period of haemodialysis did differ between <LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK> and <LINK REF="STD-Stevens-1984" TYPE="STUDY">Stevens 1984</LINK>, as participants in the <LINK REF="STD-Stevens-1984" TYPE="STUDY">Stevens 1984</LINK> trial had been receiving haemodialysis for a longer duration than those in the other trial (vaccine groups 9.9 ± 13.1 months (<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>) and 2.1± 2.1 years (<LINK REF="STD-Stevens-1984" TYPE="STUDY">Stevens 1984</LINK>), placebo groups 6.9 ± 8.6 months (<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>) and 2.0 ± 2.3 years (<LINK REF="STD-Stevens-1984" TYPE="STUDY">Stevens 1984</LINK>)).</P>
<P>Two randomised trials compared recombinant derived vaccine with plasma derived vaccine (<LINK REF="STD-Jungers-1994a" TYPE="STUDY">Jungers 1994a</LINK>; <LINK REF="STD-Seaworth-1988a" TYPE="STUDY">Seaworth 1988a</LINK>). Both of these trials were deemed to be of the same, but low methodological quality and both had inadequate allocation concealment. These two trials had far fewer participants than the trials comparing plasma vaccine with placebo. One of the two studies involved the use of two different doses of Recombivax vaccine (20 µg and 40 µg) (<LINK REF="STD-Seaworth-1988a" TYPE="STUDY">Seaworth 1988a</LINK>). For the purpose of this analysis the plasma arm from this study was used in two different comparisons, which might have introduced bias into the final analysis, although the number of participants was halved. There was significant heterogeneity between the two studies in this comparison. These two limitations preclude the formulation of conclusions based upon the analyses, even though it suggested that there was minimal difference experienced between using recombinant or plasma hepatitis B vaccines.</P>
<P>Only two trials compared the use of a reinforced series against three inoculations of recombinant hepatitis B vaccine (<LINK REF="STD-El_x002d_Reshaid-1994" TYPE="STUDY">El-Reshaid 1994</LINK>; <LINK REF="STD-Jilg-1986a" TYPE="STUDY">Jilg 1986a</LINK>). Sample sizes from both studies were very small (n = 106). The methodological quality for these two trials was also deemed to be poor with both having inadequate allocation concealment. The use of two differing doses of vaccine (20 µg and 40 µg) in a reinforced vaccination series (<LINK REF="STD-Jilg-1986a" TYPE="STUDY">Jilg 1986a</LINK>) may have affected the outcome. Bias may have also been generated as the arm of three inoculations of 40 µg in one trial was involved in two comparisons, although the number of participants was halved. No heterogeneity was exhibited in this analysis. With these limitations, no benefit was found in using a reinforced vaccination series in the CRF population. </P>
<P>Only three of seven included trials were double blinded (<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>; <LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>; <LINK REF="STD-Stevens-1984" TYPE="STUDY">Stevens 1984</LINK>), all of which assessed the use of plasma derived hepatitis B vaccine against placebo. The remaining trials were not blinded. Although non-blinded observers can introduce significant yet unintentional bias into the analysis, the important study outcomes of well-defined serologic responses and HBV infections indicate that inadequate blinding may be of less concern than issues relating to allocation. None of the studies clearly described the generation of the allocation sequence. In addition, allocation concealment was found to be inadequate for all of the studies with the exception of one (<LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>). This, ultimately limits the interpretability of the analyses undertaken in this review.</P>
<P>While this review found that the use of plasma derived hepatitis B vaccines produced seroconversions that did not differ significantly from recombinant derived vaccines, the current use of plasma vaccines is controversial. Plasma derived vaccines are human blood products and theoretically have the potential for producing adverse effects including blood borne infections. One study (<LINK REF="STD-Stevens-1984" TYPE="STUDY">Stevens 1984</LINK>) observed 101 cases of non-A, non-B hepatitis, which was likely hepatitis C, occurring in both the plasma vaccine and placebo cohorts. </P>
<P>Current practice in North American and European dialysis centres is to use a reinforced vaccination series of four inoculations of Engerix B (40 µg) vaccine for those over 20 years of age (<LINK REF="REF-Rangel-2000" TYPE="REFERENCE">Rangel 2000</LINK>; <LINK REF="REF-CDC-2001" TYPE="REFERENCE">CDC 2001</LINK>). The results of this review do not support this practice. However, the limited number of randomised trials, the low methodological quality of assessed trials, and the relatively low number of participants in these trials are obvious limitations hindering the formulation of clear conclusions.</P>
<P>The ideal dosing schedule is uncertain. The current review does not support the administration of more than three doses of vaccine. However, as previously discussed, there are concerns with the quality of this finding. Given the knowledge that CRF patients on haemodialysis have impaired immune response mechanisms (<LINK REF="REF-Girndt-2002" TYPE="REFERENCE">Girndt 2002</LINK>), it is prudent to determine the adequacy of vaccination in each patient following the third inoculation so that supplemental inoculations can be administered if needed. Further randomised clinical trials of good methodological quality are needed to resolve this issue. Additional factors that need to be considered in determining the effectiveness of hepatitis B vaccination in this population include the dosage of vaccine, the route of administration, and the use of adjuvants. <BR/>
</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Plasma derived hepatitis B vaccines are clearly more effective at achieving anti-HBs antibodies than placebo. No statistically significant difference was found between the use of recombinant or plasma vaccine. However, given the theoretical potential for transmission of blood born pathogens with plasma derived vaccines, recombinant vaccines remain the vaccine of choice in high-income nations. Overall, hepatitis B vaccines, both plasma derived and recombinant yeast derived, are effective in achieving seroconversions, although two of the three studies of plasma vaccine showed short term benefits in preventing HBV infections. This review did not show that either vaccine prevents HBV infections in chronic renal failure patients. </P>
<P>No statistically significant difference of effectiveness was observed between reinforced vaccination series and routine vaccinations of three inoculations using recombinant derived vaccine. </P>
<P>There is still insufficient information on adverse effects among chronic renal failure patients but the data reviewed do not indicate that vaccinations cause harm.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Determining the most effective method of achieving seroconversion and preventing hepatitis B infections in the chronic renal failure population using recombinant vaccines is needed since this question has not been answered by currently available randomised clinical trials. Future randomised clinical trials with large sample sizes are encouraged to compare plasma derived vaccines with recombinant vaccines among persons with impaired immunity.</P>
<P>Further randomised clinical trials of high methodological quality addressing a reinforced vaccination series (three inoculations plus one or more booster inoculations) of recombinant hepatitis B vaccines against a vaccination series of three inoculations plus placebo booster inoculations would be of benefit to determine the most optimal schedule for attaining seroconversion. To date there are insufficient randomised trials on which to formulate clinical practice recommendations. Future directions in enhancing hepatitis B vaccine effectiveness in chronic renal failure patients may involve the use of adjuvants. As this review did not assess route of administration, or compare differing doses of vaccines, these issues require future investigation. Future trials ought to adopt the CONSORT Guidelines (Consolidated Standards of Reporting Trials) (<LINK REF="REF-CONSORT-Statement" TYPE="REFERENCE">CONSORT Statement</LINK>) in their reporting.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The reviewers would like to thank the following people: Ms. Ellen Crumley, Centres for Health Evidence Demonstration Project; Mr. B. Poluha and Mr. M. Tennenhouse, Neil John McLean Library, University of Manitoba. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>RJS, CAH, JZ, JU, and AN developed the protocol and undertook data extraction of included trials.<BR/>RJS, CAH, JZ, and JU undertook final analysis and revisions of the review.<BR/>SPT and MEKM advised on methodology and review process.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Crosnier-1981" NAME="Crosnier 1981" YEAR="1981">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Crosnier J, Jungers P, Courouce AM, Laplanche A, Benhamou E, Degos F, et al</AU>
<TI>Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, Haemodialysis patients</TI>
<SO>Lancet</SO>
<YR>1981</YR>
<VL>1</VL>
<NO>8224</NO>
<PG>797-800</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Crosnier J</AU>
<TI>Hepatitis B in haemodialysis: vaccination against HBs antigen</TI>
<SO>Proceedings of the European Dialysis and Transplantation Association. European Dialysis and Transplant Association</SO>
<YR>1981</YR>
<VL>18</VL>
<PG>231-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Degos F, Courouce AM, Vitviski L, Lacour B, Crosnier J</AU>
<TI>Incidence of hepatitis during a placebo controlled study of vaccine against hepatitis B virus</TI>
<SO>Liver</SO>
<YR>1982</YR>
<VL>3 Pt 2</VL>
<NO>2</NO>
<PG>317</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Desmyter-1983" NAME="Desmyter 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Desmyter J, Colaert J, De Groote G, Reynders M, Reerink-Brongers EE, Leli PN, et al</AU>
<TI>Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Double-blind placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>1983</YR>
<VL>2</VL>
<NO>8363</NO>
<PG>1323-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El_x002d_Reshaid-1994" NAME="El-Reshaid 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El-Reshaid K, Al-Mufti S, Johny KV, Sugathan TN</AU>
<TI>Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients</TI>
<SO>Vaccine</SO>
<YR>1994</YR>
<VL>12</VL>
<NO>3</NO>
<PG>223-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jilg-1986a" NAME="Jilg 1986a" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jilg W, Schmidt M, Weinel B, Kuttler T, Brass H, Bommer J, et al</AU>
<TI>Immunogenicity of recombinant hepatitis B vaccine in dialysis patients</TI>
<SO>Journal of Hepatology</SO>
<YR>1986</YR>
<VL>3</VL>
<NO>2</NO>
<PG>190-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jilg-1986b" NAME="Jilg 1986b" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jilg W, Schmidt M, Weinel B, Kuttler T, Brass H, Bommer J, et al</AU>
<TI>Immunogenicity of recombinant hepatitis B vaccine in dialysis patients</TI>
<SO>Journal of Hepatology</SO>
<YR>1986</YR>
<VL>3</VL>
<NO>2</NO>
<PG>190-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jungers-1994a" NAME="Jungers 1994a" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;[Recombinant vaccine and extracting vaccine against hepatitis B in patients with kidney insufficiency: comparative immunogenicity]  Presse Med  1994  23  6   277-80&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jungers P, Chauveau P, Courouce AM, Abbassi A, Devillier P, Marie FN, et al</AU>
<TI>[Recombinant vaccine and extracting vaccine against hepatitis B in patients with kidney insufficiency: comparative immunogenicity]</TI>
<SO>La Presse Medicale</SO>
<YR>1994</YR>
<VL>23</VL>
<NO>6</NO>
<PG>277-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jungers P, Chauveau P, Courouce AM, Devillier P, Excler JL, Bailleux F, et al</AU>
<TI>Immunogenicity of the recombinant GenHevac B Pasteur vaccine against hepatitis B in chronic uremic patients</TI>
<SO>The Journal of Infectious Diseases</SO>
<YR>1994</YR>
<VL>169</VL>
<NO>2</NO>
<PG>399-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seaworth-1988a" NAME="Seaworth 1988a" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Seaworth B, Drucker J, Starling J, Drucker R, Stevens C, Hamilton J</AU>
<TI>Hepatitis B vaccine in patients with chronic renal failure before dialysis</TI>
<SO>The Journal of Infectious Diseases</SO>
<YR>1988</YR>
<VL>157</VL>
<NO>2</NO>
<PG>332-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seaworth-1988b" NAME="Seaworth 1988b" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Seaworth B, Drucker J, Starling J, Drucker R, Stevens C, Hamilton J</AU>
<TI>Hepatitis B vaccine in patients with chronic renal failure before dialysis</TI>
<SO>The Journal of infectious diseases</SO>
<YR>1988</YR>
<VL>157</VL>
<NO>2</NO>
<PG>332-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stevens-1984" NAME="Stevens 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W</AU>
<TI>Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1984</YR>
<VL>311</VL>
<NO>8</NO>
<PG>496-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Andre-1987" NAME="Andre 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andre FE, Safary A</AU>
<TI>Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1987</YR>
<VL>63 Suppl2</VL>
<PG>169-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chang--1996" NAME="Chang  1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chang PC, Schrander-van der Meer AM, van Dorp WT, van Leer E</AU>
<TI>Intracutaneous versus intramuscular hepatitis B vaccination in primary non-responding haemodialysis patients</TI>
<SO>Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - Eurpoean Renal Association</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>1</NO>
<PG>191-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Charest-2000" NAME="Charest 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Charest AF, McDougall J, Goldstein MB</AU>
<TI>A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients</TI>
<SO>American journal of kidney diseases: the official journal of the National Kidney Foundation</SO>
<YR>2000</YR>
<VL>36</VL>
<NO>5</NO>
<PG>976-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jungers-1994b" NAME="Jungers 1994b" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jungers P, Devillier P, Salomon H, Cerisier JE, Courouce AM</AU>
<TI>Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>344</VL>
<NO>8926</NO>
<PG>856-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Propst-1998" NAME="Propst 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Propst T, Propst A, Lhotta K, Vogel W, Konig P</AU>
<TI>Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination</TI>
<SO>American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation</SO>
<YR>1998</YR>
<VL>32</VL>
<NO>6</NO>
<PG>1041-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vincent-1998" NAME="Vincent 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vincent L, John GT, Abraham P, Jacob CK</AU>
<TI>An intradermal vaccine protocol against hepatitis B in a haemodialysis population</TI>
<SO>The National Medical Journal of India</SO>
<YR>1998</YR>
<VL>11</VL>
<NO>1</NO>
<PG>48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vlassopoulos-1999" NAME="Vlassopoulos 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vlassopoulos DA, Arvanitis DK, Lilis DS, Louizou KI, Hadjiconstantinou VE</AU>
<TI>Lower long-term efficiency of intradermal hepatitis B vaccine compared to the intramuscular route in hemodialysis patients</TI>
<SO>The International Journal of Artificial Organs</SO>
<YR>1999</YR>
<VL>22</VL>
<NO>11</NO>
<PG>739-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alexander-1998" MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]" NAME="Alexander 1998" TYPE="JOURNAL_ARTICLE">
<AU>Alexander D, Peacock E, Curry G, Jacob G</AU>
<TI>Immunizing the ESRD patient population: providers face challenges</TI>
<SO>Nephrology News &amp; Issues</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>10</NO>
<PG>42-4;45-6;66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CDC-2001" MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]" NAME="CDC 2001" TYPE="BOOK_SECTION">
<AU>Center for Disease Control</AU>
<TI>Recommendations for preventing transmission of infections among chronic hemodialysis patients</TI>
<SO>MMWR. Recommendations and Reports: Morbidity and Mortality Weekly Report: Recommendations and Reports/Centers for Disease Control</SO>
<YR>2001</YR>
<VL>50 (RR-5)</VL>
<PG>1-43</PG>
<PB>CDC</PB>
<CY>Altanta, Georgia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chatenoud-1986" MODIFIED="2008-11-09 12:46:51 +0100" MODIFIED_BY="[Empty name]" NAME="Chatenoud 1986" TYPE="JOURNAL_ARTICLE">
<AU>Chatenoud L, Dugas B, Beaurain G, Touam M, Drueke T, Vasquez A, et al</AU>
<TI>Presence of preactivated T cells in hemodialyzed patients: their possible role in altered immunity</TI>
<SO>Proceedings of the National Academy of Sciences of the United States of America</SO>
<YR>1986</YR>
<VL>83</VL>
<NO>19</NO>
<PG>7457-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 3094009"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chatenoud-1990" MODIFIED="2008-11-09 12:46:51 +0100" MODIFIED_BY="[Empty name]" NAME="Chatenoud 1990" TYPE="JOURNAL_ARTICLE">
<AU>Chatenoud L, Herbelin A, Beaurain G, Descamps-Latscha B</AU>
<TI>Immune deficiency of the uremic patient</TI>
<SO>Advances in nephrology from the Necker Hospital</SO>
<YR>1990</YR>
<VL>19</VL>
<PG>259-74</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 2105582"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2001" MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]" NAME="Clarke 2001" TYPE="OTHER">
<AU>Clarke M, Oxman AD, editors</AU>
<TI>Cochrane Reviewers' Handbook 4.1.4 [updated October 2001]</TI>
<SO>In: The Cochrane Library, Issue 4. 2001. Oxfrod: Update Software. Updated quarterly</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CONSORT-Statement" MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]" NAME="CONSORT Statement" TYPE="OTHER">
<AU>Moher D, Schulz KF, Altman DG for the CONSORT Group</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials</TI>
<SO>www.consort-statement.org</SO>
<YR>(accessed 21 November 2002)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dukes-1993" MODIFIED="2008-11-09 12:46:51 +0100" MODIFIED_BY="[Empty name]" NAME="Dukes 1993" TYPE="JOURNAL_ARTICLE">
<AU>Dukes CS, Street AC, Starling JF, Hamilton JD</AU>
<TI>Hepatitis B vaccination and booster in predialysis patients: a 4-year analysis</TI>
<SO>Vaccine</SO>
<YR>1993</YR>
<VL>11</VL>
<NO>12</NO>
<PG>1229-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Engels-2000" MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]" NAME="Engels 2000" TYPE="JOURNAL_ARTICLE">
<AU>Engels EA, Schmid CH, Terrin N, Olkin I, Lau J</AU>
<TI>Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses</TI>
<SO>Statistics in Medicine</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>13</NO>
<PG>1707-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fabrizi-2000" MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]" NAME="Fabrizi 2000" TYPE="JOURNAL_ARTICLE">
<AU>Fabrizi F, Martin P</AU>
<TI>Hepatitis B virus infection in dialysis patients</TI>
<SO>American Journal of Nephrology</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>1</NO>
<PG>1-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fabrizi-2001" MODIFIED="2008-11-09 12:46:51 +0100" MODIFIED_BY="[Empty name]" NAME="Fabrizi 2001" TYPE="JOURNAL_ARTICLE">
<AU>Fabrizi F, Martin P, Lunghi G, Ponticelli C</AU>
<TI>Novel evidence on hepatitis B virus infection in dialysis</TI>
<SO>The International Journal of Artificial Organs</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>1</NO>
<PG>8-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feuerhake-1984" MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]" NAME="Feuerhake 1984" TYPE="JOURNAL_ARTICLE">
<AU>Feuerhake A, Muller R, Lauchart W, Pichlmayr R, Schmidt FW</AU>
<TI>HBV - vaccination in recipients of kidney allografts</TI>
<SO>Vaccine</SO>
<YR>1984</YR>
<VL>2</VL>
<NO>4</NO>
<PG>255-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 6241770"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fivush-1998" MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]" NAME="Fivush 1998" TYPE="JOURNAL_ARTICLE">
<AU>Fivush BA, Neu AM</AU>
<TI>Immunization guidelines for pediatric renal disease</TI>
<SO>Seminars in Nephrology</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>3</NO>
<PG>256-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Geerlings-1991" MODIFIED="2008-11-09 12:46:51 +0100" MODIFIED_BY="[Empty name]" NAME="Geerlings 1991" TYPE="JOURNAL_ARTICLE">
<AU>Geerlings W, Tufveson G, Brunner FP, Ehrich JH, Fassbinder W, Landais P, et al</AU>
<TI>Combined report on regular dialysis and transplantation in Europe, XXI, 1990</TI>
<SO>Nephrology, Dialysis, Tranpslantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association</SO>
<YR>1991</YR>
<VL>6 Suppl4</VL>
<PG>5-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Girndt-2002" MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]" NAME="Girndt 2002" TYPE="JOURNAL_ARTICLE">
<AU>Girndt M, Kohler H</AU>
<TI>Hepatitis B virus infection in hemodialysis patients</TI>
<SO>Seminars in Nephrology</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>4</NO>
<PG>340-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 12118399"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Huang-1997" MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]" NAME="Huang 1997" TYPE="JOURNAL_ARTICLE">
<AU>Huang CC</AU>
<TI>Hepatitis in patients with end-stage renal disease</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>9-10</NO>
<PG>S236-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]" NAME="Jadad 1996" NOTES="&lt;p&gt;Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials  1996 17 1-12&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 12:46:52 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jefferson-2000" MODIFIED="2008-11-09 12:46:51 +0100" MODIFIED_BY="[Empty name]" NAME="Jefferson 2000" TYPE="COCHRANE_REVIEW">
<AU>Jefferson T, Demicheli V, Deeks J, MacMillan A, Sassi F, Pratt M</AU>
<TI>Vaccines for preventing hepatitis B in health-care workers</TI>
<SO>Cochrane Library</SO>
<YR>2000</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnson-1992" MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]" NAME="Johnson 1992" TYPE="JOURNAL_ARTICLE">
<AU>Johnson DW, Fleming SJ</AU>
<TI>The use of vaccines in renal failure</TI>
<SO>Clinical Pharmacokinetics</SO>
<YR>1992</YR>
<VL>22</VL>
<NO>6</NO>
<PG>434-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2001" MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]" NAME="Jüni 2001" NOTES="&lt;p&gt;J&amp;#252;ni P, Altman DG, Egger M   Systematic reviews in health care: assessing the quality of controlled clinical trials &lt;br&gt;BMJ 2001   323&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 12:46:52 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in health care: Assessing the quality of controlled clinical trials</TI>
<SO>British Medical Journal</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7303</NO>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebure-1993" MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]" NAME="Lefebure 1993" TYPE="JOURNAL_ARTICLE">
<AU>Lefebure AF</AU>
<TI>Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant patients</TI>
<SO>Vaccine</SO>
<YR>1993</YR>
<VL>11</VL>
<NO>4</NO>
<PG>397-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MacKellar-2001" MODIFIED="2008-11-09 12:46:51 +0100" MODIFIED_BY="[Empty name]" NAME="MacKellar 2001" TYPE="JOURNAL_ARTICLE">
<AU>MacKellar DA, Valleroy LA, Secura GM, McFarland W, Shehan D, Ford W, et al</AU>
<TI>Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men</TI>
<SO>American Journal of Public Health</SO>
<YR>2001</YR>
<VL>91</VL>
<NO>6</NO>
<PG>965-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 1998" NOTES="&lt;p&gt;Moher D, Pham B, Jones A, Cook DJ, Jadad A, Moher M, et al&lt;br&gt;Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysis  Lancet  1998 352   609-13&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 12:46:52 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad A, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysis</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1999" MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 1999" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF</AU>
<TI>Improving the quality of reports of meta-analyses of randomised controlled trials: the QUORUM statement</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9193</NO>
<PG>1896-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petrosillo-1993" MODIFIED="2008-11-09 12:46:51 +0100" MODIFIED_BY="[Empty name]" NAME="Petrosillo 1993" TYPE="JOURNAL_ARTICLE">
<AU>Petrosillo N, Puro V, Ippolito G</AU>
<TI>Prevalence of human immunodeficiency virus, hepatitis B virus and hepatitis C virus among dialysis patients. The Italian Multicentric Study on Nosocomial and Occupational Risk of Blood-Borne Infections in Dialysis</TI>
<SO>Nephron</SO>
<YR>1993</YR>
<VL>64</VL>
<NO>4</NO>
<PG>636-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 8366992"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Popper-1990" MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]" NAME="Popper 1990" TYPE="BOOK">
<AU>Popper H, Schaffner F</AU>
<SO>Progress in liver diseases</SO>
<YR>1990</YR>
<VL>9</VL>
<PB>W.B. Saunders Company</PB>
<CY>Toronto</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rangel-2000" MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]" NAME="Rangel 2000" TYPE="JOURNAL_ARTICLE">
<AU>Rangel MC, Coronado VG, Euler GL, Strikas RA</AU>
<TI>Vaccine recommendations for patients on chronic dialysis. The Advisory Committee on Immunization Practices and the American Academy of Pediatrics</TI>
<SO>Seminars in Dialysis</SO>
<YR>2000</YR>
<VL>13</VL>
<NO>2</NO>
<PG>101-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Revillard-1979" MODIFIED="2008-11-09 12:46:51 +0100" MODIFIED_BY="[Empty name]" NAME="Revillard 1979" TYPE="JOURNAL_ARTICLE">
<AU>Revillard JP</AU>
<TI>Immunologic alterations in chronic renal insufficiency</TI>
<SO>Advances in Nephrology from the Necker Hospital</SO>
<YR>1979</YR>
<VL>8</VL>
<PG>365-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 115248"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" NOTES="&lt;p&gt;Schulz KF, Chalmers I, Hayes RJ, Altman DG&lt;br&gt;Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials  JAMA   1995  273   408-12&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 12:46:52 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Specter-1999" MODIFIED="2008-11-09 12:46:51 +0100" MODIFIED_BY="[Empty name]" NAME="Specter 1999" TYPE="BOOK_SECTION">
<AU>Specter SC</AU>
<TI>Hepatitis B vaccines</TI>
<SO>Viral Hepatitis: Diagnosis, Therapy, and Prevention</SO>
<YR>1999</YR>
<PG>377-91</PG>
<ED>Specter SC</ED>
<PB>Humana Press</PB>
<CY>Totowa, NJ</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ISBN 0-89603-424-0"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tokars-1998" MODIFIED="2008-11-09 12:46:51 +0100" MODIFIED_BY="[Empty name]" NAME="Tokars 1998" TYPE="JOURNAL_ARTICLE">
<AU>Tokars JI, Miller ER, Alter MJ, Arduino MJ</AU>
<TI>National surveillance of dialysis associated diseases in the United States, 1995</TI>
<SO>ASAIO Journal (American Society for Artificial Internal Organs: 1992)</SO>
<YR>1998</YR>
<VL>44</VL>
<NO>1</NO>
<PG>98-107</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 9466509"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tokars-2000" MODIFIED="2008-11-09 12:46:51 +0100" MODIFIED_BY="[Empty name]" NAME="Tokars 2000" TYPE="JOURNAL_ARTICLE">
<AU>Tokars JI, Miller ER, Alter MJ, Arduino MJ</AU>
<TI>National surveillance of dialysis-associated diseases in the United States, 1997</TI>
<SO>Seminars in Dialysis</SO>
<YR>2000</YR>
<VL>13</VL>
<NO>2</NO>
<PG>75-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Torres-1996" MODIFIED="2008-11-09 12:46:51 +0100" MODIFIED_BY="[Empty name]" NAME="Torres 1996" TYPE="JOURNAL_ARTICLE">
<AU>Torres JR</AU>
<TI>Hepatitis B and hepatitis delta virus infection in South America</TI>
<SO>Gut</SO>
<YR>1996</YR>
<VL>38 Suppl 2</VL>
<PG>S48-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walker-1999" MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]" NAME="Walker 1999" TYPE="JOURNAL_ARTICLE">
<AU>Walker A</AU>
<TI>Meta-style and expert review</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9193</NO>
<PG>1834-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zannolli-1997" MODIFIED="2008-11-09 12:46:51 +0100" MODIFIED_BY="[Empty name]" NAME="Zannolli 1997" TYPE="JOURNAL_ARTICLE">
<AU>Zannolli R, Morgese G</AU>
<TI>Hepatitis B vaccine: current issues</TI>
<SO>The Annals of Pharmacotherapy</SO>
<YR>1997</YR>
<VL>31</VL>
<NO>9</NO>
<PG>1059-67</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-09 12:41:13 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-11-09 12:41:13 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Crosnier-1981">
<CHAR_METHODS>
<P>Randomised clinical trial, double-blind, placebo controlled, withdrawals/dropouts discussed.<BR/>43 dropouts.</P>
<P>* For assessment of methodological quality, please see Additional Table 04.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Haemodialysis patients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Institut Pasteur production vaccine (plasma) 5 µg at 0,1, and 2 months versus placebo at 0,1, and 2 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Anti-HBs seroconversion active hepatitis B infections, and adverse events, deaths at 12 months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Plasma vaccine versus placebo.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Desmyter-1983">
<CHAR_METHODS>
<P>Randomised clinical trial, double-blind, placebo controlled, withdrawals/dropouts discussed.<BR/>13 dropouts.</P>
<P>* For assessment of methodological quality, please see Additional Table 04.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Haemodialysis patients <BR/>(vaccine = 94 &gt; 1 year, placebo = 80 &gt; 1 year).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>CLB (plasma) vaccine 3 µg at 0, 1, 2, and 5 versus placebo at 0, 1, 2, and 5 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Anti-HBs seroconversion, partial seroconversion, active hepatitis B infections, adverse events, deaths at 14 months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Plasma vaccine versus placebo.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-El_x002d_Reshaid-1994">
<CHAR_METHODS>
<P>Randomised clinical trial, single-blinded, withdrawals/dropouts discussed.<BR/>9 dropouts.</P>
<P>* For assessment of methodological quality, please see Additional Table 04.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Peritoneal and haemodialysis patients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Engerix B (recombinant) 40 µg at 0, 1, and 6 versus Engerix B (recombinant) 40 µg at 0, 1, 2, and 6 months.<BR/>(Also Engerix B (recombinant) 20 µg at 0, 1, and 6 months was assessed, but this arm was excluded for the purposes of this review as this was for healthy staff and not related to the 3 inoculation versus reinforced series debate).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Anti-HBs seroconversion, active infections at 24 months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Recombinant vaccine schedule.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-09 12:40:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jilg-1986a">
<CHAR_METHODS>
<P>Randomised clinical trial, not blinded.</P>
<P>* For assessment of methodological quality, please see Additional Table 04.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-09 12:40:06 +0100" MODIFIED_BY="[Empty name]">
<P>Dialysis patients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Merck Sharp Dohme (recombinant) 40 µg at 0, 1, 6 versus Merck Sharp Dohme (recombinant) 40 µg at 0, 1, 2, 3, 4, and 5 months.</P>
<P>Merck Sharp Dohme (recombinant) 40 µg at 0, 1, 6 versus Merck Sharp Dohme (recombinant) 20 µg at 0, 1, 2, 3, 4, 5.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Anti-HBs seroconversion at 10 months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-09 12:40:11 +0100" MODIFIED_BY="[Empty name]">
<P>Recombinant vaccine schedule (groups 1 and 3 combined).</P>
<P>Recombinant vaccine schedule (groups 1 and 2 combined).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jilg-1986b">
<CHAR_METHODS>
<P>Please see Jilg 1986a</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-09 12:40:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jungers-1994a">
<CHAR_METHODS MODIFIED="2008-11-09 12:40:39 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial, withdrawals/dropouts discussed.<BR/>16 dropouts.<BR/>(Not blinded)</P>
<P>* For assessment of methodological quality, please see Additional Table 04.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Chronic uremic patients (not on dialysis).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hevac B (plasma) vaccine 5 µg at 0, 1, 2, 4, and 12 months versus GenHevac B (recombinant) vaccine 20 µg at 0, 1, 2, 4, and 12 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Anti-HBs seroconversion, partial seroconversion at 12 months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Recombinant versus plasma.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-09 12:41:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Seaworth-1988a">
<CHAR_METHODS MODIFIED="2008-11-09 12:40:49 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial, withdrawals/dropouts, discussed.<BR/>8 dropouts.<BR/>(Not blinded)</P>
<P>* For assessment of methodological quality, please see Additional Table 04.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Chronic renal failure patients (mean 4.5 mg/dL, range 2.0 to 9.8).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Recombivax (recombinant) vaccine 20 ug at 0, 1, 6 months versus recombivax (recombinant) vaccine 40 ug at 0, 1, 6 months versus heptavax B (plasma) vaccine 40 µg at 0, 1, 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-09 12:41:13 +0100" MODIFIED_BY="[Empty name]">
<P>Anti-HBs seroconversion, partial seroconversion, deaths at 12 months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Recombinant versus plasma (groups 1 and 3 combined).</P>
<P>Recombinant versus plasma (groups 2 and 3 combined).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Seaworth-1988b">
<CHAR_METHODS>
<P>Please see Seaworth 1988a</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stevens-1984">
<CHAR_METHODS>
<P>Randomised clinical trial, double-blind, placebo controlled, withdrawals/dropouts discussed.<BR/>98 dropouts.</P>
<P>* For assessment of methodological quality, please see Additional Table 04.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Haemodialysis patients<BR/>N = 1311.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Heptavax B (plasma) vaccine 40 µg at 0, 1, and 6 months versus placebo at 0, 1, and 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Anti-HBs seroconversion, active hepatitis B infections, deaths at 24 months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Plasma versus placebo.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Andre-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>A randomised clinical trial of 6100 people of which 270 were on chronic haemodialysis (plasma derived vaccine 20 µg at 0, 1, and 6 months or 0, 1, 2, and 12 months versus recombinant vaccine 2.5 µg, 5 µg, 10 µg, 20 µg at 0, 1, and 6 months or 0, 1, 2, and 12 months).<BR/>We were unable to extract data specific to haemodialysis patients from the results presented in this publication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chang--1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>A randomised clinical trial of recombinant vaccine of different doses, schedules, and routes (HepB-DNA 40 µg at 0,1,and 3 months intramuscularly versus HepB-DNA 10 µg at 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 months intracutaneously). This trial was excluded because it assessed route of vaccine administration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Charest-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>A randomised clinical trial of recombinant vaccines of different routes, doses, and schedules (Engerix B 40 µg at 0, 1, 2, and 6 months intramuscularly versus recombinant hepatitis B vaccine 5 µg intradermally at 0 month; then every two weeks until adequate titres at least 1000 IU/L or until 2 years). This trial was excluded because it assessed route of vaccine administration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jungers-1994b">
<CHAR_REASON_FOR_EXCLUSION>
<P>A randomised clinical trial of recombinant vaccine with interleukin-2 among non-responders. This trial involved the use of an adjuvant and was therefore excluded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Propst-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>A randomised clinical trial of recombinant vaccine of different dose, schedule, and route (Engerix B 40 µg IM at 0, 1, and 6 months and booster at 8 and 12 months if titres less than 10 IU/L versus Engerix B 20 µg subcutaneously every two weeks up to 240 µg versus Engerix B 20 µg intradermally every 2 weeks up to 240 µg). This trial was excluded because it assessed route of vaccine administration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vincent-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>A randomised clinical trial of recombinant vaccine of different dose, route and schedule (40 µg intramuscularly at 0, 4, and 8 months versus 20 µg intradermally at 0, 0.25, 0.5, 0.75, 1, and 1.25 months). This trial was excluded because it assessed route of vaccine administration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vlassopoulos-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>A randomised clinical trial of recombinant vaccine of different dose, route and schedule (Engerix, SKB 5 µg intradermally at 0, 0.5, 1, 1.5, 2, 2.5, 3, and 3.5 months and intramuscular booster at 12 versus Engerix, SKB 20 µg intramuscularly at 0, 1, 2, and 12 months). This trial was excluded because it assessed route of vaccine administration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Crosnier-1981">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Desmyter-1983">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-El_x002d_Reshaid-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jilg-1986a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jilg-1986b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jungers-1994a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Seaworth-1988a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Seaworth-1988b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Stevens-1984">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-11-09 13:50:40 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-11-09 13:50:40 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Criteria for assessing anti-HBs response (North America)</TITLE>
<TABLE COLS="3" ROWS="4">
<TR>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>Response</P>
</TD>
<TD>
<P>Sample ratio units (SRU)</P>
</TD>
<TD>
<P>International units (IU/L)</P>
</TD>
</TR>
<TR>
<TD>
<P>Inadequate</P>
</TD>
<TD>
<P>2.1 - 9.9 SRU</P>
</TD>
<TD>
<P>2.1 - 9.9 IU/L</P>
</TD>
</TR>
<TR>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>&gt; 10 SRU</P>
</TD>
<TD>
<P>&gt; 10 IU/L</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-11-09 13:50:40 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE>Criteria for assessing anti-HBs response (Europe)</TITLE>
<TABLE COLS="3" ROWS="5">
<TR>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>Response</P>
</TD>
<TD>
<P>Sample ratio units (SRU)</P>
</TD>
<TD>
<P>International units (IU/L)</P>
</TD>
</TR>
<TR>
<TD>
<P>Inadequate</P>
</TD>
<TD>
<P>2.1 - 9.9 SRU</P>
</TD>
<TD>
<P>2.1 - 9.9 IU/L</P>
</TD>
</TR>
<TR>
<TD>
<P>Low response</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>10 - 100 IU/L</P>
</TD>
</TR>
<TR>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>&gt; 10 SRU</P>
</TD>
<TD>
<P>&gt; 100 IU/L</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2008-11-09 12:46:52 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE>Methodological quality of included studies</TITLE>
<TABLE COLS="5" ROWS="9">
<TR>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>Included study</P>
</TD>
<TD>
<P>Generation of allocation sequence</P>
</TD>
<TD>
<P>Allocation concealment</P>
</TD>
<TD>
<P>Blinding</P>
</TD>
<TD>
<P>Follow-up</P>
</TD>
</TR>
<TR>
<TD>
<P>Crosnier 1981</P>
</TD>
<TD>
<P>Unclear - not described.</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Adequate double blinded and placebo controlled.</P>
</TD>
<TD>
<P>Number and reason for dropouts and withdrawals mentioned.</P>
</TD>
</TR>
<TR>
<TD>
<P>Desmyter 1983</P>
</TD>
<TD>
<P>Unclear - not described. A code was used, however, this was insufficient information to determine appropriateness.</P>
</TD>
<TD>
<P>Adequate. An independent physician had sole access to the code.</P>
</TD>
<TD>
<P>Adequate double blinded and placebo controlled.</P>
</TD>
<TD>
<P>Number and reason for dropouts described.</P>
</TD>
</TR>
<TR>
<TD>
<P>El-Reshaid 1994</P>
</TD>
<TD>
<P>Unclear - not described.</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Not double blinded.</P>
</TD>
<TD>
<P>Number of dropouts and withdrawals given but not reasons.</P>
</TD>
</TR>
<TR>
<TD>
<P>Jilg 1986</P>
</TD>
<TD>
<P>Unclear - not described.</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Not double blinded.</P>
</TD>
<TD>
<P>Number and reasons for dropouts and withdrawals not reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>Jungers 1994</P>
</TD>
<TD>
<P>Unclear - not described.</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Not double blinded.</P>
</TD>
<TD>
<P>Number and reasons for dropouts and withdrawals mentioned.</P>
</TD>
</TR>
<TR>
<TD>
<P>Seaworth 1988</P>
</TD>
<TD>
<P>Unclear - not described.</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Not double blinded.</P>
</TD>
<TD>
<P>Number and reasons for dropouts and withdrawals described.</P>
</TD>
</TR>
<TR>
<TD>
<P>Stevens 1984</P>
</TD>
<TD>
<P>Unclear - not described.</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Adequate double blinded and placebo controlled.</P>
</TD>
<TD>
<P>Number and reasons for dropouts and withdrawals described.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Plasma vaccine versus placebo</NAME>
<DICH_OUTCOME CHI2="0.36218011112820986" CI_END="36.76069667774265" CI_START="14.394762007323916" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="23.003510164745038" ESTIMABLE="YES" EVENTS_1="413" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="1.5653837334113596" LOG_CI_START="1.1582044889598193" LOG_EFFECT_SIZE="1.3617941111855894" METHOD="MH" NO="1" P_CHI2="0.8343602584825808" P_Q="0.0" P_Z="2.8845892961320144E-39" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="933" TOTAL_2="917" WEIGHT="100.00000000000001" Z="13.11003666642022">
<NAME>Seroconversion to anti-HBs</NAME>
<GROUP_LABEL_1>Plasma vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Plasma</GRAPH_LABEL_2>
<DICH_DATA CI_END="782.6140293331881" CI_START="3.023486233047946" EFFECT_SIZE="48.64383561643836" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="0" LOG_CI_END="2.8935476289050355" LOG_CI_START="0.4805079954572833" LOG_EFFECT_SIZE="1.6870278121811597" ORDER="37" O_E="0.0" SE="1.4174314254260378" STUDY_ID="STD-Crosnier-1981" TOTAL_1="72" TOTAL_2="66" VAR="2.0091118457852892" WEIGHT="2.847359831944282"/>
<DICH_DATA CI_END="54.20938236089866" CI_START="11.112565846824216" EFFECT_SIZE="24.543946932006634" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="6" LOG_CI_END="1.7340744591385244" LOG_CI_START="1.0458143473710875" LOG_EFFECT_SIZE="1.389944403254806" ORDER="38" O_E="0.0" SE="0.40428739659469226" STUDY_ID="STD-Desmyter-1983" TOTAL_1="201" TOTAL_2="200" VAR="0.16344829904531397" WEIGHT="34.99984032251376"/>
<DICH_DATA CI_END="38.840366932839565" CI_START="11.825001745293385" EFFECT_SIZE="21.43099173553719" ESTIMABLE="YES" EVENTS_1="239" EVENTS_2="11" LOG_CI_END="1.5892833241235758" LOG_CI_START="1.0728012135088962" LOG_EFFECT_SIZE="1.331042268816236" ORDER="39" O_E="0.0" SE="0.30338414840274297" STUDY_ID="STD-Stevens-1984" TOTAL_1="660" TOTAL_2="651" VAR="0.09204194150205758" WEIGHT="62.15279984554196"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="42.524827793246494" CI_START="10.887735082204193" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="21.517412935323378" ESTIMABLE="YES" EVENTS_1="173" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="1.6286425635875055" LOG_CI_START="1.0369375451731826" LOG_EFFECT_SIZE="1.3327900543803441" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="1.051739983214562E-18" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="201" TOTAL_2="200" WEIGHT="100.0" Z="8.829468820592385">
<NAME>Full and partial anti-HBs seroconversion</NAME>
<GROUP_LABEL_1>Plasma vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Plasma</GRAPH_LABEL_2>
<DICH_DATA CI_END="42.524827793246494" CI_START="10.887735082204193" EFFECT_SIZE="21.51741293532338" ESTIMABLE="YES" EVENTS_1="173" EVENTS_2="8" LOG_CI_END="1.6286425635875055" LOG_CI_START="1.0369375451731826" LOG_EFFECT_SIZE="1.3327900543803441" ORDER="40" O_E="0.0" SE="0.34757045680365267" STUDY_ID="STD-Desmyter-1983" TOTAL_1="201" TOTAL_2="200" VAR="0.12080522244269978" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.288288322336083" CI_END="1.2449253737623927" CI_START="0.2004750623490572" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.49957631241376826" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="83" I2="83.72434022104888" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.09514331871322526" LOG_CI_START="-0.6979396427833139" LOG_EFFECT_SIZE="-0.3013981620350443" METHOD="MH" NO="3" P_CHI2="0.0021460210390635837" P_Q="0.0" P_Z="0.13630200773717527" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.5403333141697368" TOTALS="YES" TOTAL_1="933" TOTAL_2="917" WEIGHT="100.0" Z="1.4897042838508445">
<NAME>Hepatitis B virus infection</NAME>
<GROUP_LABEL_1>Plasma vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Plasma</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8572461097895108" CI_START="0.22226893357521563" EFFECT_SIZE="0.4365079365079365" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="21" LOG_CI_END="-0.06689447705090962" LOG_CI_START="-0.6531212341957284" LOG_EFFECT_SIZE="-0.36000785562331905" ORDER="41" O_E="0.0" SE="0.34435249901611514" STUDY_ID="STD-Crosnier-1981" TOTAL_1="72" TOTAL_2="66" VAR="0.11857864357864357" WEIGHT="32.93707693599027"/>
<DICH_DATA CI_END="0.5162279105847887" CI_START="0.10441910476938757" EFFECT_SIZE="0.23217247097844113" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="30" LOG_CI_END="-0.2871585184181206" LOG_CI_START="-0.9812200345057059" LOG_EFFECT_SIZE="-0.6341892764619133" ORDER="42" O_E="0.0" SE="0.40769517020976187" STUDY_ID="STD-Desmyter-1983" TOTAL_1="201" TOTAL_2="200" VAR="0.1662153518123667" WEIGHT="30.7164034005155"/>
<DICH_DATA CI_END="1.720943445344426" CI_START="0.6763066216691738" EFFECT_SIZE="1.0788352272727273" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="32" LOG_CI_END="0.23576659852139376" LOG_CI_START="-0.1698563604080079" LOG_EFFECT_SIZE="0.03295511905669294" ORDER="43" O_E="0.0" SE="0.2382649339411597" STUDY_ID="STD-Stevens-1984" TOTAL_1="660" TOTAL_2="651" VAR="0.05677017874598519" WEIGHT="36.34651966349422"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.2248787202678373" CI_END="2.052710475720597" CI_START="0.24849296848915087" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7142017358986102" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="117" I2="55.0537298554585" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.3123276986818871" LOG_CI_START="-0.6046858958222634" LOG_EFFECT_SIZE="-0.14617909857018815" METHOD="MH" NO="4" P_CHI2="0.13580341423905795" P_Q="0.0" P_Z="0.5320583537936636" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.39543320492186274" TOTALS="YES" TOTAL_1="273" TOTAL_2="266" WEIGHT="100.0" Z="0.6248670035148592">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Plasma vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Plasma</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.461461622002211" CI_START="0.06388412540245478" EFFECT_SIZE="0.3055555555555556" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.16478741526546564" LOG_CI_START="-1.19460704648359" LOG_EFFECT_SIZE="-0.5149098156090621" ORDER="44" O_E="0.0" SE="0.7985150359425066" STUDY_ID="STD-Crosnier-1981" TOTAL_1="72" TOTAL_2="66" VAR="0.6376262626262627" WEIGHT="28.086746202488726"/>
<DICH_DATA CI_END="1.1862372276191193" CI_START="0.8346344896741471" EFFECT_SIZE="0.9950248756218906" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="111" LOG_CI_END="0.0741715493515559" LOG_CI_START="-0.07850367286457127" LOG_EFFECT_SIZE="-0.0021660617565076663" ORDER="45" O_E="0.0" SE="0.08968218128429173" STUDY_ID="STD-Desmyter-1983" TOTAL_1="201" TOTAL_2="200" VAR="0.008042893639908566" WEIGHT="71.91325379751127"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.02022824129283333" CI_END="2.441963777951683" CI_START="0.7945600796680101" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3929418271972756" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.3877392176955233" LOG_CI_START="-0.09987325858020218" LOG_EFFECT_SIZE="0.14393297955766057" METHOD="MH" NO="5" P_CHI2="0.8869014871260043" P_Q="0.0" P_Z="0.24723947217925824" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="273" TOTAL_2="266" WEIGHT="100.0" Z="1.1570805500105223">
<NAME>Deaths</NAME>
<GROUP_LABEL_1>Plasma vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Plasma</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.145099544798752" CI_START="0.3798319166769568" EFFECT_SIZE="1.5277777777777777" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7885289224391762" LOG_CI_START="-0.42040854498526303" LOG_EFFECT_SIZE="0.18406018872695656" ORDER="46" O_E="0.0" SE="0.7101358527020935" STUDY_ID="STD-Crosnier-1981" TOTAL_1="72" TOTAL_2="66" VAR="0.5042929292929293" WEIGHT="16.268291416058958"/>
<DICH_DATA CI_END="2.526835030659436" CI_START="0.7407921707286742" EFFECT_SIZE="1.3681592039800996" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="16" LOG_CI_END="0.40257688908533235" LOG_CI_START="-0.13030361626578474" LOG_EFFECT_SIZE="0.1361366364097738" ORDER="47" O_E="0.0" SE="0.3130166466442895" STUDY_ID="STD-Desmyter-1983" TOTAL_1="201" TOTAL_2="200" VAR="0.097979421076436" WEIGHT="83.73170858394104"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4400205006691258" CI_END="0.6159340108873783" CI_START="0.17705840297120384" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.33023672161552126" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="51" I2="30.55654419257671" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.2104658142034667" LOG_CI_START="-0.7518834573417531" LOG_EFFECT_SIZE="-0.4811746357726099" METHOD="MH" NO="6" P_CHI2="0.2301362934325477" P_Q="0.0" P_Z="4.944199552240742E-4" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.06265759821975654" TOTALS="YES" TOTAL_1="273" TOTAL_2="266" WEIGHT="100.0" Z="3.4837614486368533">
<NAME>Sensitivity analysis for hepatitis B virus (HBV) infection excluding Stevens 1984</NAME>
<GROUP_LABEL_1>Plasma vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Plasma</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8572461097895108" CI_START="0.22226893357521563" EFFECT_SIZE="0.4365079365079365" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="21" LOG_CI_END="-0.06689447705090962" LOG_CI_START="-0.6531212341957284" LOG_EFFECT_SIZE="-0.36000785562331905" ORDER="48" O_E="0.0" SE="0.34435249901611514" STUDY_ID="STD-Crosnier-1981" TOTAL_1="72" TOTAL_2="66" VAR="0.11857864357864357" WEIGHT="55.80780791831276"/>
<DICH_DATA CI_END="0.5162279105847887" CI_START="0.10441910476938757" EFFECT_SIZE="0.23217247097844113" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="30" LOG_CI_END="-0.2871585184181206" LOG_CI_START="-0.9812200345057059" LOG_EFFECT_SIZE="-0.6341892764619133" ORDER="49" O_E="0.0" SE="0.40769517020976187" STUDY_ID="STD-Desmyter-1983" TOTAL_1="201" TOTAL_2="200" VAR="0.1662153518123667" WEIGHT="44.192192081687246"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Recombinant vaccine versus plasma vaccine</NAME>
<DICH_OUTCOME CHI2="10.223370317812376" CI_END="1.5269373090073555" CI_START="0.2795033595094971" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6532871555663305" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="50" I2="80.43697980385822" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.18382120672827784" LOG_CI_START="-0.5536129677143447" LOG_EFFECT_SIZE="-0.1848958804930334" METHOD="MH" NO="1" P_CHI2="0.006025946363451773" P_Q="0.0" P_Z="0.32568705265902675" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.43192376429965346" TOTALS="YES" TOTAL_1="101" TOTAL_2="80" WEIGHT="100.0" Z="0.9828382768674191">
<NAME>Anti-HBs seroconversion</NAME>
<GROUP_LABEL_1>Recombinant vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Plasma vaccine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Plasma</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Recombinant</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4999780171308639" CI_START="0.9004271234220349" EFFECT_SIZE="1.162162162162162" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="37" LOG_CI_END="0.17608489431653457" LOG_CI_START="-0.045551431291351564" LOG_EFFECT_SIZE="0.06526673151259149" ORDER="50" O_E="0.0" SE="0.13019027477957817" STUDY_ID="STD-Jungers-1994a" TOTAL_1="60" TOTAL_2="60" VAR="0.01694950764718207" WEIGHT="41.80208824857329"/>
<DICH_DATA CI_END="1.5112347008371765" CI_START="0.3722122048205965" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.17933191725964762" LOG_CI_START="-0.4292093904762475" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="51" O_E="0.0" SE="0.3574601764921203" STUDY_ID="STD-Seaworth-1988a" TOTAL_1="20" TOTAL_2="10" VAR="0.1277777777777778" WEIGHT="33.52472472507784"/>
<DICH_DATA CI_END="0.6276570870864338" CI_START="0.06635679520432715" EFFECT_SIZE="0.20408163265306123" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="-0.20227756304699535" LOG_CI_START="-1.178114597010032" LOG_EFFECT_SIZE="-0.6901960800285136" ORDER="52" O_E="0.0" SE="0.5732115042211108" STUDY_ID="STD-Seaworth-1988b" TOTAL_1="21" TOTAL_2="10" VAR="0.3285714285714285" WEIGHT="24.673187026348867"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.88083458367557" CI_END="1.3769473271540067" CI_START="0.6851527357537935" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9712977031726377" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="54" I2="48.464693434426586" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.1389173273564965" LOG_CI_START="-0.16421260383452055" LOG_EFFECT_SIZE="-0.012647638239011997" METHOD="MH" NO="2" P_CHI2="0.1436441436183057" P_Q="0.0" P_Z="0.8700829918101752" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.048057077203484296" TOTALS="YES" TOTAL_1="101" TOTAL_2="80" WEIGHT="100.00000000000001" Z="0.1635530700683884">
<NAME>Full and partial seroconversion to anti-HBs</NAME>
<GROUP_LABEL_1>Recombinant vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Plasma vaccine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Plasma</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Recombinant</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.493992687227744" CI_START="0.96386013955133" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="40" LOG_CI_END="0.17434847170668194" LOG_CI_START="-0.015985979611432347" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="53" O_E="0.0" SE="0.11180339887498951" STUDY_ID="STD-Jungers-1994a" TOTAL_1="60" TOTAL_2="60" VAR="0.012500000000000004" WEIGHT="52.35617855753926"/>
<DICH_DATA CI_END="1.4723367690852776" CI_START="0.4989985260012664" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.16800715798204063" LOG_CI_START="-0.30190073724326705" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="54" O_E="0.0" SE="0.27602622373694163" STUDY_ID="STD-Seaworth-1988a" TOTAL_1="20" TOTAL_2="10" VAR="0.07619047619047617" WEIGHT="25.51790405832193"/>
<DICH_DATA CI_END="1.2455729395229187" CI_START="0.37153194918290744" EFFECT_SIZE="0.6802721088435374" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.09536916447373318" LOG_CI_START="-0.43000383397008535" LOG_EFFECT_SIZE="-0.1673173347481761" ORDER="55" O_E="0.0" SE="0.3086066999241838" STUDY_ID="STD-Seaworth-1988b" TOTAL_1="21" TOTAL_2="10" VAR="0.09523809523809523" WEIGHT="22.12591738413882"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.019676677564654" CI_END="1.9204158078848153" CI_START="0.2923862481210469" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7493351539196531" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="50" I2="88.9131280893097" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.2833952722028196" LOG_CI_START="-0.5340430575198982" LOG_EFFECT_SIZE="-0.12532389265853933" METHOD="MH" NO="3" P_CHI2="0.0026709185460296325" P_Q="0.0" P_Z="0.5478561260165182" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.4122742314375699" TOTALS="YES" TOTAL_1="101" TOTAL_2="80" WEIGHT="100.0" Z="0.6009757729281441">
<NAME>Sensitivity analysis for anti-HBs seroconversion - combining both recombinant arms of Seaworth 1988</NAME>
<GROUP_LABEL_1>Recombinant vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Plasma vaccine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Plasma</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Recombinant</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4999780171308639" CI_START="0.9004271234220349" EFFECT_SIZE="1.162162162162162" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="37" LOG_CI_END="0.17608489431653457" LOG_CI_START="-0.045551431291351564" LOG_EFFECT_SIZE="0.06526673151259149" ORDER="56" O_E="0.0" SE="0.13019027477957817" STUDY_ID="STD-Jungers-1994a" TOTAL_1="60" TOTAL_2="60" VAR="0.01694950764718207" WEIGHT="53.715728049335944"/>
<DICH_DATA CI_END="0.799670396325511" CI_START="0.2535461653129197" EFFECT_SIZE="0.450281425891182" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="-0.09708898119975409" LOG_CI_START="-0.5959429534301783" LOG_EFFECT_SIZE="-0.34651596731496626" ORDER="57" O_E="0.0" SE="0.2930292926551392" STUDY_ID="STD-Seaworth-1988a" TOTAL_1="41" TOTAL_2="20" VAR="0.08586616635397122" WEIGHT="46.28427195066406"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.608869393904678" CI_END="1.5742721746134039" CI_START="0.5846202040097217" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9593494253343338" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="50" I2="61.669219534853504" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.19707981932802446" LOG_CI_START="-0.23312617984701717" LOG_EFFECT_SIZE="-0.018023180259496358" METHOD="MH" NO="4" P_CHI2="0.10626754787897019" P_Q="0.0" P_Z="0.8695558726432163" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.08445252742037954" TOTALS="YES" TOTAL_1="80" TOTAL_2="80" WEIGHT="100.0" Z="0.16422264804872336">
<NAME>Sensitivity analysis for anti-HBs seroconversion (excluding the low dose recombinant arm of Seaworth 1988)</NAME>
<GROUP_LABEL_1>Recombinant vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Plasma vaccine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Plasma</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Recombinant</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4999780171308639" CI_START="0.9004271234220349" EFFECT_SIZE="1.162162162162162" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="37" LOG_CI_END="0.17608489431653457" LOG_CI_START="-0.045551431291351564" LOG_EFFECT_SIZE="0.06526673151259149" ORDER="58" O_E="0.0" SE="0.13019027477957817" STUDY_ID="STD-Jungers-1994a" TOTAL_1="60" TOTAL_2="60" VAR="0.01694950764718207" WEIGHT="62.97692589627967"/>
<DICH_DATA CI_END="1.238384152715186" CI_START="0.3870284836716846" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.09285538581912764" LOG_CI_START="-0.4122570715541515" LOG_EFFECT_SIZE="-0.1597008428675119" ORDER="59" O_E="0.0" SE="0.29670555780805324" STUDY_ID="STD-Seaworth-1988a" TOTAL_1="20" TOTAL_2="20" VAR="0.08803418803418804" WEIGHT="37.02307410372034"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Reinforced recombinant vaccination series versus primary recombinant vaccination series</NAME>
<DICH_OUTCOME CHI2="2.586673883144913" CI_END="2.1615744615404693" CI_START="0.850649656486988" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3560024237369364" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="17" I2="22.680628082563967" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.33477020062800616" LOG_CI_START="-0.07024926903695489" LOG_EFFECT_SIZE="0.1322604657955256" METHOD="MH" NO="1" P_CHI2="0.2743538817902058" P_Q="0.0" P_Z="0.20052205819611535" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03856361713147275" TOTALS="YES" TOTAL_1="63" TOTAL_2="43" WEIGHT="100.0" Z="1.2800656213004176">
<NAME>Seroconversion to anti-HBs</NAME>
<GROUP_LABEL_1>Reinforced series</GROUP_LABEL_1>
<GROUP_LABEL_2>Primary series</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Standard</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Reinforced</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.299006355265643" CI_START="1.0681158284563967" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.6333680871395144" LOG_CI_START="0.028618350943334366" LOG_EFFECT_SIZE="0.3309932190414244" ORDER="60" O_E="0.0" SE="0.3552329886011098" STUDY_ID="STD-El_x002d_Reshaid-1994" TOTAL_1="24" TOTAL_2="24" VAR="0.1261904761904762" WEIGHT="34.35506637001128"/>
<DICH_DATA CI_END="2.142921812653059" CI_START="0.5443035733328649" EFFECT_SIZE="1.08" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.33100632552022596" LOG_CI_START="-0.2641588145463265" LOG_EFFECT_SIZE="0.03342375548694973" ORDER="61" O_E="0.0" SE="0.34960294939005054" STUDY_ID="STD-Jilg-1986a" TOTAL_1="20" TOTAL_2="9" VAR="0.12222222222222223" WEIGHT="35.20296211133044"/>
<DICH_DATA CI_END="2.2337815834334" CI_START="0.49603472837937196" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.3490407060459338" LOG_CI_START="-0.30448791662362934" LOG_EFFECT_SIZE="0.02227639471115221" ORDER="62" O_E="0.0" SE="0.3838859479749573" STUDY_ID="STD-Jilg-1986b" TOTAL_1="19" TOTAL_2="10" VAR="0.14736842105263162" WEIGHT="30.441971518658278"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-11-09 12:43:32 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-11-09 12:43:32 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-11-09 12:43:09 +0100" MODIFIED_BY="[Empty name]">Search Strategies</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-09 12:43:32 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="5">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search strategy</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search performed</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Hepato-Biliary Group Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>('renal failure' or 'kidney failure' or 'renal disease' or 'kidney disease' or dialysis or h*emodialysis) and 'hepatitis b' and (vaccin* or immun* or booster or re-vaccin* or revaccin*) or (engerix or heptavax or recombivax)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>October 2002</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PubMed/MEDLINE MESH Terms</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>kidney[MESH]; renal dialysis[MESH]; dialysis[MESH], peritoneal dialysis, continuous ambulatory[MESH]; dialysis, peritoneal[MESH]; kidney failure, chronic[MESH}; kidney failure[MESH]; uremia[MESH]; hepatitis B[MESH]; hepatitis B surface antigens[MESH]; antigens, surface[MESH]; hepatitis B core antigens[MESH]; hepatitis B e antigens[MESH]; hepatitis B surface antigens[MESH]; vaccine[MESH]; hepatitis B vaccines[MESH]; vaccination[MESH]; immunization, secondary[MESH]; immunity[MESH]; immune sera[MESH]; vaccine, hepatitis B[MESH]; adjuvants, immunologic[MESH]; adjuvants, pharmaceutic[MESH]; randomized controlled trial[MESH].</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>July 2003</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PubMed/MEDLINE Search Strategy</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(renal OR kidney OR kidney[MESH] OR "renal dialysis"[MESH] OR dialysis OR dialysis[MESH] OR hemodialysis OR haemodialysis OR CAPD OR "continuous ambulatory peritoneal dialysis" OR CCPD OR "continuous cyclical peritoneal dialysis" OR ESRD OR "end stage renal disease" OR "chronic renal failure" OR "renal failure" OR ESRF OR "end stage renal failure" OR "chronic renal insufficiency" OR "renal insufficiency" OR "peritoneal dialysis, continuous ambulatory"[MESH] OR "dialysis, peritoneal"[MESH] OR "kidney failure, chronic"[MESH] OR "kidney failure"[MESH] OR uremia OR uraemia OR uremic OR uremia[MESH]) AND ( "hepatitis b" OR "hepatitis B"[MESH] OR "australian antigen" OR HBSAG OR "surface antigen" OR "hepatitis b surface antigens"[MESH] OR "antigens, surface"[MESH] OR "hepatitis b core antigens"[MESH] OR "hepatitis b e antigens"[MESH] OR "hepatitis b surface antigens"[MESH]) AND ( vaccine[MESH] OR vaccin* OR immun* OR booster OR "re-vaccinat*" OR revaccinat* OR engerix OR heptavax OR recombivax OR "hepatitis b vaccines"[MESH] OR "secondary vaccination" OR "viral vaccines"[MESH] OR "viral hepatitis vaccines"[MESH] OR vaccination[MESH] OR "immunization, secondary"[MESH] OR immunity[MESH] OR "immune sera"[MESH] OR "vaccine, hepatitis b"[MESH] OR adjuvant* OR "Adjuvants, Immunologic"[MESH] OR "Adjuvants, Pharmaceutic"[MESH]) AND ("trial" OR "clinical trial" OR "randomized controlled trial" OR "randomised controlled trial" OR "randomized controlled trial"[MESH] OR "randomized controlled trial.pt" OR review[pt])</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>July 2003</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 explode "chronic-kidney-disease"/ all subheadings<BR/>#2 explode "chronic-kidney-failure"/ all subheadings<BR/>#3 explode "kidney"/ all subheadings<BR/>#4 explode "kidney-disease"/ all subheadings<BR/>#5 explode "kidney-failure"/ all subheadings<BR/>#6 explode "hemodialysis"/ all subheadings<BR/>#7 explode "continuous-ambulatory-peritoneal-dialysis"/ all subheadings<BR/>#8 explode "dialysis"/ all subheadings<BR/>#9 explode "peritoneal-dialysis"/ all subheadings<BR/>#10 explode "uremia"/ all subheadings<BR/>#11 (renal or kidney) and (failure or disease* or insufficien*)<BR/>#12 ur*emi*<BR/>#13 dialys*<BR/>#14 h*emodialys*<BR/>#15 CAPD or CCPD or ESRD or ESRF<BR/>#16 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15<BR/>#17 explode "hepatitis-B"/ all subheadings<BR/>#18 explode "hepatitis-B-antigen"/ all subheadings<BR/>#19 explode "hepatitis-B-core-antigen"/ all subheadings<BR/>#20 explode "hepatitis-Be-antigen"/ all subheadings<BR/>#21 explode "hepatitis-B-surface-antigen"/ all subheadings<BR/>#22 hepatitis B<BR/>#23 australian antigen<BR/>#24 HBsAg<BR/>#25 surface antigen*<BR/>#26 #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25<BR/>#27 explode "hepatitis-B-vaccine"/ all subheadings<BR/>#28 explode "vaccine"/ all subheadings<BR/>#29 explode "vaccination"/ all subheadings<BR/>#30 explode "immunization"/ all subheadings<BR/>#31 explode "immunity"/ all subheadings<BR/>#32 explode "antiserum"/ all subheadings<BR/>#33 vaccin* or immun* or booster or re*vaccin*<BR/>#34 #27 or #28 or #29 or #30 or #31 or #32 or #33<BR/>#35 #26 and #34<BR/>#36 energix or heptavax or recombivax<BR/>#37 #35 or #36<BR/>#38 #16 and #37<BR/>#39 random* or blind* or placebo or meta-analysis<BR/>#40 #38 and #39<BR/>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13 November 2003</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>